1
|
Rathnayake MSB, Boos MA, Farrugia BL, van Osch GJVM, Stok KS. Glycosaminoglycan-Mediated Interactions in Articular, Auricular, Meniscal, and Nasal Cartilage. Tissue Eng Part B Rev 2024. [PMID: 38613808 DOI: 10.1089/ten.teb.2023.0346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/15/2024]
Abstract
Glycosaminoglycans (GAGs) are ubiquitous components in the cartilage extracellular matrix (ECM). Ultrastructural arrangement of ECM and GAG-mediated interactions with collagen are known to govern the mechanics in articular cartilage, but these interactions are less clear in other cartilage types. Therefore, this article reviews the current literature on ultrastructure of articular, auricular, meniscal, and nasal septal cartilage, seeking insight into GAG-mediated interactions influencing mechanics. Ultrastructural features of these cartilages are discussed to highlight differences between them. GAG-mediated interactions are reviewed under two categories: interactions with chondrocytes and interactions with other fibrillar macromolecules of the ECM. Moreover, efforts to replicate GAG-mediated interactions to improve mechanical integrity of tissue-engineered cartilage constructs are discussed. In conclusion, studies exploring cartilage specific GAGs are poorly represented in the literature, and the ultrastructure of nasal septal and auricular cartilage is less studied compared with articular and meniscal cartilages. Understanding the contribution of GAGs in cartilage mechanics at the ultrastructural level and translating that knowledge to engineered cartilage will facilitate improvement of cartilage tissue engineering approaches.
Collapse
Affiliation(s)
- Manula S B Rathnayake
- Department of Biomedical Engineering, The University of Melbourne, Parkville, Australia
| | - Manuela A Boos
- Department of Biomedical Engineering, The University of Melbourne, Parkville, Australia
| | - Brooke L Farrugia
- Department of Biomedical Engineering, The University of Melbourne, Parkville, Australia
- Graeme Clark Institute for Biomedical Engineering, The University of Melbourne, Parkville, Australia
| | - Gerjo J V M van Osch
- Department of Otorhinolaryngology, Head and Neck Surgery and Department of Orthopaedics and Sports Medicine, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
- Department of Biomechanical Engineering, Faculty of Mechanical Engineering, Delft University of Technology, Delft, The Netherlands
| | - Kathryn S Stok
- Department of Biomedical Engineering, The University of Melbourne, Parkville, Australia
| |
Collapse
|
2
|
Kalogeropoulou M, Díaz-Payno PJ, Mirzaali MJ, van Osch GJVM, Fratila-Apachitei LE, Zadpoor AA. 4D printed shape-shifting biomaterials for tissue engineering and regenerative medicine applications. Biofabrication 2024; 16:022002. [PMID: 38224616 DOI: 10.1088/1758-5090/ad1e6f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2023] [Accepted: 01/15/2024] [Indexed: 01/17/2024]
Abstract
The existing 3D printing methods exhibit certain fabrication-dependent limitations for printing curved constructs that are relevant for many tissues. Four-dimensional (4D) printing is an emerging technology that is expected to revolutionize the field of tissue engineering and regenerative medicine (TERM). 4D printing is based on 3D printing, featuring the introduction of time as the fourth dimension, in which there is a transition from a 3D printed scaffold to a new, distinct, and stable state, upon the application of one or more stimuli. Here, we present an overview of the current developments of the 4D printing technology for TERM, with a focus on approaches to achieve temporal changes of the shape of the printed constructs that would enable biofabrication of highly complex structures. To this aim, the printing methods, types of stimuli, shape-shifting mechanisms, and cell-incorporation strategies are critically reviewed. Furthermore, the challenges of this very recent biofabrication technology as well as the future research directions are discussed. Our findings show that the most common printing methods so far are stereolithography (SLA) and extrusion bioprinting, followed by fused deposition modelling, while the shape-shifting mechanisms used for TERM applications are shape-memory and differential swelling for 4D printing and 4D bioprinting, respectively. For shape-memory mechanism, there is a high prevalence of synthetic materials, such as polylactic acid (PLA), poly(glycerol dodecanoate) acrylate (PGDA), or polyurethanes. On the other hand, different acrylate combinations of alginate, hyaluronan, or gelatin have been used for differential swelling-based 4D transformations. TERM applications include bone, vascular, and cardiac tissues as the main target of the 4D (bio)printing technology. The field has great potential for further development by considering the combination of multiple stimuli, the use of a wider range of 4D techniques, and the implementation of computational-assisted strategies.
Collapse
Affiliation(s)
- Maria Kalogeropoulou
- Department of Biomechanical Engineering, Faculty of Mechanical Engineering, Delft University of Technology, Delft, CD 2628, The Netherlands
| | - Pedro J Díaz-Payno
- Department of Biomechanical Engineering, Faculty of Mechanical Engineering, Delft University of Technology, Delft, CD 2628, The Netherlands
- Department of Orthopedics and Sports Medicine, Erasmus MC University Medical Center, 3015 CN Rotterdam, The Netherlands
| | - Mohammad J Mirzaali
- Department of Biomechanical Engineering, Faculty of Mechanical Engineering, Delft University of Technology, Delft, CD 2628, The Netherlands
| | - Gerjo J V M van Osch
- Department of Biomechanical Engineering, Faculty of Mechanical Engineering, Delft University of Technology, Delft, CD 2628, The Netherlands
- Department of Orthopedics and Sports Medicine, Erasmus MC University Medical Center, 3015 CN Rotterdam, The Netherlands
- Department of Otorhinolaryngology, Head and Neck Surgery, Erasmus MC University Medical Center, 3015 CN Rotterdam, The Netherlands
| | - Lidy E Fratila-Apachitei
- Department of Biomechanical Engineering, Faculty of Mechanical Engineering, Delft University of Technology, Delft, CD 2628, The Netherlands
| | - Amir A Zadpoor
- Department of Biomechanical Engineering, Faculty of Mechanical Engineering, Delft University of Technology, Delft, CD 2628, The Netherlands
- Department of Orthopedics, Leiden University Medical Center, Leiden, The Netherlands
| |
Collapse
|
3
|
Velot É, Balmayor ER, Bertoni L, Chubinskaya S, Cicuttini F, de Girolamo L, Demoor M, Grigolo B, Jones E, Kon E, Lisignoli G, Murphy M, Noël D, Vinatier C, van Osch GJVM, Cucchiarini M. Women's contribution to stem cell research for osteoarthritis: an opinion paper. Front Cell Dev Biol 2023; 11:1209047. [PMID: 38174070 PMCID: PMC10762903 DOI: 10.3389/fcell.2023.1209047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Accepted: 09/18/2023] [Indexed: 01/05/2024] Open
Affiliation(s)
- Émilie Velot
- Laboratory of Molecular Engineering and Articular Physiopathology (IMoPA), French National Centre for Scientific Research, University of Lorraine, Nancy, France
| | - Elizabeth R. Balmayor
- Experimental Orthopaedics and Trauma Surgery, Department of Orthopaedic, Trauma, and Reconstructive Surgery, RWTH Aachen University Hospital, Aachen, Germany
- Rehabilitation Medicine Research Center, Mayo Clinic, Rochester, MN, United States
| | - Lélia Bertoni
- CIRALE, USC 957, BPLC, École Nationale Vétérinaire d'Alfort, Maisons-Alfort, France
| | | | - Flavia Cicuttini
- Musculoskeletal Unit, Monash University and Rheumatology, Alfred Hospital, Melbourne, VIC, Australia
| | - Laura de Girolamo
- IRCCS Ospedale Galeazzi - Sant'Ambrogio, Orthopaedic Biotechnology Laboratory, Milan, Italy
| | - Magali Demoor
- Normandie University, UNICAEN, BIOTARGEN, Caen, France
| | - Brunella Grigolo
- IRCCS Istituto Ortopedico Rizzoli, Laboratorio RAMSES, Bologna, Italy
| | - Elena Jones
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom
| | - Elizaveta Kon
- IRCCS Humanitas Research Hospital, Milan, Italy
- Department ofBiomedical Sciences, Humanitas University, Milan, Italy
| | - Gina Lisignoli
- IRCCS Istituto Ortopedico Rizzoli, Laboratorio di Immunoreumatologia e Rigenerazione Tissutale, Bologna, Italy
| | - Mary Murphy
- Regenerative Medicine Institute (REMEDI), School of Medicine, University of Galway, Galway, Ireland
| | - Danièle Noël
- IRMB, University of Montpellier, Inserm, CHU Montpellier, Montpellier, France
| | - Claire Vinatier
- Nantes Université, Oniris, INSERM, Regenerative Medicine and Skeleton, Nantes, France
| | - Gerjo J. V. M. van Osch
- Department of Orthopaedics and Sports Medicine and Department of Otorhinolaryngology, Department of Biomechanical Engineering, University Medical Center Rotterdam, Faculty of Mechanical, Maritime and Materials Engineering, Delft University of Technology, Delft, Netherlands
| | - Magali Cucchiarini
- Center of Experimental Orthopedics, Saarland University and Saarland University Medical Center, Homburg/Saar, Germany
| |
Collapse
|
4
|
Ji E, Leijsten L, Witte-Bouma J, Rouchon A, Di Maggio N, Banfi A, van Osch GJVM, Farrell E, Lolli A. In Vitro Mineralisation of Tissue-Engineered Cartilage Reduces Endothelial Cell Migration, Proliferation and Tube Formation. Cells 2023; 12:cells12081202. [PMID: 37190110 DOI: 10.3390/cells12081202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2023] [Revised: 04/14/2023] [Accepted: 04/18/2023] [Indexed: 05/17/2023] Open
Abstract
Tissue engineering bone via endochondral ossification requires the generation of a cartilage template which undergoes vascularisation and remodelling. While this is a promising route for bone repair, achieving effective cartilage vascularisation remains a challenge. Here, we investigated how mineralisation of tissue-engineered cartilage affects its pro-angiogenic potential. To generate in vitro mineralised cartilage, human mesenchymal stromal cell (hMSC)-derived chondrogenic pellets were treated with β-glycerophosphate (BGP). After optimising this approach, we characterised the changes in matrix components and pro-angiogenic factors by gene expression analysis, histology and ELISA. Human umbilical vein endothelial cells (HUVECs) were exposed to pellet-derived conditioned media, and migration, proliferation and tube formation were assessed. We established a reliable strategy to induce in vitro cartilage mineralisation, whereby hMSC pellets are chondrogenically primed with TGF-β for 2 weeks and BGP is added from week 2 of culture. Cartilage mineralisation determines loss of glycosaminoglycans, reduced expression but not protein abundance of collagen II and X, and decreased VEGFA production. Finally, the conditioned medium from mineralised pellets showed a reduced ability to stimulate endothelial cell migration, proliferation and tube formation. The pro-angiogenic potential of transient cartilage is thus stage-dependent, and this aspect must be carefully considered in the design of bone tissue engineering strategies.
Collapse
Affiliation(s)
- Encheng Ji
- Department of Oral and Maxillofacial Surgery, Erasmus MC University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
| | - Lieke Leijsten
- Department of Oral and Maxillofacial Surgery, Erasmus MC University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
| | - Janneke Witte-Bouma
- Department of Oral and Maxillofacial Surgery, Erasmus MC University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
| | - Adelin Rouchon
- Department of Biomedicine, Basel University Hospital, University of Basel, 4031 Basel, Switzerland
| | - Nunzia Di Maggio
- Department of Biomedicine, Basel University Hospital, University of Basel, 4031 Basel, Switzerland
| | - Andrea Banfi
- Department of Biomedicine, Basel University Hospital, University of Basel, 4031 Basel, Switzerland
| | - Gerjo J V M van Osch
- Department of Orthopaedics and Sports Medicine, Erasmus MC University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
- Department of Otorhinolaryngology, Erasmus MC University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
- Department of Biomechanical Engineering, University of Technology Delft, 2628 CD Delft, The Netherlands
| | - Eric Farrell
- Department of Oral and Maxillofacial Surgery, Erasmus MC University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
| | - Andrea Lolli
- Department of Oral and Maxillofacial Surgery, Erasmus MC University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
| |
Collapse
|
5
|
Xu J, Fahmy-Garcia S, Wesdorp MA, Kops N, Forte L, De Luca C, Misciagna MM, Dolcini L, Filardo G, Labberté M, Vancíková K, Kok J, van Rietbergen B, Nickel J, Farrell E, Brama PAJ, van Osch GJVM. Effectiveness of BMP-2 and PDGF-BB Adsorption onto a Collagen/Collagen-Magnesium-Hydroxyapatite Scaffold in Weight-Bearing and Non-Weight-Bearing Osteochondral Defect Bone Repair: In Vitro, Ex Vivo and In Vivo Evaluation. J Funct Biomater 2023; 14:jfb14020111. [PMID: 36826910 PMCID: PMC9961206 DOI: 10.3390/jfb14020111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2023] [Revised: 02/10/2023] [Accepted: 02/14/2023] [Indexed: 02/19/2023] Open
Abstract
Despite promising clinical results in osteochondral defect repair, a recently developed bi-layered collagen/collagen-magnesium-hydroxyapatite scaffold has demonstrated less optimal subchondral bone repair. This study aimed to improve the bone repair potential of this scaffold by adsorbing bone morphogenetic protein 2 (BMP-2) and/or platelet-derived growth factor-BB (PDGF-BB) onto said scaffold. The in vitro release kinetics of BMP-2/PDGF-BB demonstrated that PDGF-BB was burst released from the collagen-only layer, whereas BMP-2 was largely retained in both layers. Cell ingrowth was enhanced by BMP-2/PDFG-BB in a bovine osteochondral defect ex vivo model. In an in vivo semi-orthotopic athymic mouse model, adding BMP-2 or PDGF-BB increased tissue repair after four weeks. After eight weeks, most defects were filled with bone tissue. To further investigate the promising effect of BMP-2, a caprine bilateral stifle osteochondral defect model was used where defects were created in weight-bearing femoral condyle and non-weight-bearing trochlear groove locations. After six months, the adsorption of BMP-2 resulted in significantly less bone repair compared with scaffold-only in the femoral condyle defects and a trend to more bone repair in the trochlear groove. Overall, the adsorption of BMP-2 onto a Col/Col-Mg-HAp scaffold reduced bone formation in weight-bearing osteochondral defects, but not in non-weight-bearing osteochondral defects.
Collapse
Affiliation(s)
- Jietao Xu
- Department of Orthopedics and Sports Medicine, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands
| | - Shorouk Fahmy-Garcia
- Department of Orthopedics and Sports Medicine, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands
- Department of Oral and Maxillofacial Surgery, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands
| | - Marinus A. Wesdorp
- Department of Orthopedics and Sports Medicine, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands
| | - Nicole Kops
- Department of Orthopedics and Sports Medicine, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands
| | - Lucia Forte
- Fin-Ceramica Faenza S.p.A, 48018 Faenza, Italy
| | | | | | | | - Giuseppe Filardo
- Applied and Translational Research Center, IRCCS Rizzoli Orthopaedic Institute, 40136 Bologna, Italy
| | - Margot Labberté
- School of Veterinary Medicine, University College Dublin, D04 V1W8 Dublin, Ireland
| | - Karin Vancíková
- School of Veterinary Medicine, University College Dublin, D04 V1W8 Dublin, Ireland
| | - Joeri Kok
- Department of Biomedical Engineering, Eindhoven University of Technology, 5612 AZ Eindhoven, The Netherlands
| | - Bert van Rietbergen
- Department of Biomedical Engineering, Eindhoven University of Technology, 5612 AZ Eindhoven, The Netherlands
| | - Joachim Nickel
- Department Tissue Engineering and Regenerative Medicine, University Hospital Würzburg, 97070 Würzburg, Germany
| | - Eric Farrell
- Department of Oral and Maxillofacial Surgery, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands
| | - Pieter A. J. Brama
- School of Veterinary Medicine, University College Dublin, D04 V1W8 Dublin, Ireland
| | - Gerjo J. V. M. van Osch
- Department of Orthopedics and Sports Medicine, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands
- Department of Otorhinolaryngology, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands
- Department of Biomechanical Engineering, Delft University of Technology, 2628 CD Delft, The Netherlands
- Correspondence: ; Tel.: +31-107043661
| |
Collapse
|
6
|
Díaz-Payno PJ, Kalogeropoulou M, Muntz I, Kingma E, Kops N, D'Este M, Koenderink GH, Fratila-Apachitei LE, van Osch GJVM, Zadpoor AA. Swelling-Dependent Shape-Based Transformation of a Human Mesenchymal Stromal Cells-Laden 4D Bioprinted Construct for Cartilage Tissue Engineering. Adv Healthc Mater 2023; 12:e2201891. [PMID: 36308047 DOI: 10.1002/adhm.202201891] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2022] [Revised: 10/10/2022] [Indexed: 01/18/2023]
Abstract
3D bioprinting is usually implemented on flat surfaces, posing serious limitations in the fabrication of multilayered curved constructs. 4D bioprinting, combining 3D bioprinting with time-dependent stimuli-induced transformation, enables the fabrication of shape-changing constructs. Here, a 4D biofabrication method is reported for cartilage engineering based on the differential swelling of a smart multi-material system made from two hydrogel-based materials: hyaluronan and alginate. Two ink formulations are used: tyramine-functionalized hyaluronan (HAT, high-swelling) and alginate with HAT (AHAT, low-swelling). Both inks have similar elastic, shear-thinning, and printability behavior. The inks are 3D printed into a bilayered scaffold before triggering the shape-change by using liquid immersion as stimulus. In time (4D), the differential swelling between the two zones leads to the scaffold's self-bending. Different designs are made to tune the radius of curvature and shape. A bioprinted formulation of AHAT and human bone marrow cells demonstrates high cell viability. After 28 days in chondrogenic medium, the curvature is clearly present while cartilage-like matrix production is visible on histology. A proof-of-concept of the recently emerged technology of 4D bioprinting with a specific application for the design of curved structures potentially mimicking the curvature and multilayer cellular nature of native cartilage is demonstrated.
Collapse
Affiliation(s)
- Pedro J Díaz-Payno
- Department of Biomechanical Engineering, Faculty of Mechanical, Maritime and Materials Engineering, Delft University of Technology, Delft, 2628CD, Netherlands.,Department of Orthopedics and Sports Medicine, Erasmus MC University Medical Center, Rotterdam, 3015GD, Netherlands
| | - Maria Kalogeropoulou
- Department of Biomechanical Engineering, Faculty of Mechanical, Maritime and Materials Engineering, Delft University of Technology, Delft, 2628CD, Netherlands
| | - Iain Muntz
- Department of Bionanoscience, Kavli Institute of Nanoscience Delft, Delft University of Technology, Delft, 2628CD, Netherlands
| | - Esther Kingma
- Department of Biomechanical Engineering, Faculty of Mechanical, Maritime and Materials Engineering, Delft University of Technology, Delft, 2628CD, Netherlands
| | - Nicole Kops
- Department of Orthopedics and Sports Medicine, Erasmus MC University Medical Center, Rotterdam, 3015GD, Netherlands
| | - Matteo D'Este
- AO Research Institute Davos, Davos, 7270, Switzerland
| | - Gijsje H Koenderink
- Department of Bionanoscience, Kavli Institute of Nanoscience Delft, Delft University of Technology, Delft, 2628CD, Netherlands
| | - Lidy E Fratila-Apachitei
- Department of Biomechanical Engineering, Faculty of Mechanical, Maritime and Materials Engineering, Delft University of Technology, Delft, 2628CD, Netherlands
| | - Gerjo J V M van Osch
- Department of Biomechanical Engineering, Faculty of Mechanical, Maritime and Materials Engineering, Delft University of Technology, Delft, 2628CD, Netherlands.,Department of Orthopedics and Sports Medicine, Erasmus MC University Medical Center, Rotterdam, 3015GD, Netherlands.,Department of Otorhinolaryngology, Erasmus MC University Medical Center, Rotterdam, 3015GD, Netherlands
| | - Amir A Zadpoor
- Department of Biomechanical Engineering, Faculty of Mechanical, Maritime and Materials Engineering, Delft University of Technology, Delft, 2628CD, Netherlands
| |
Collapse
|
7
|
Lesage R, Ferrao Blanco MN, Narcisi R, Welting T, van Osch GJVM, Geris L. An integrated in silico-in vitro approach for identifying therapeutic targets against osteoarthritis. BMC Biol 2022; 20:253. [DOI: 10.1186/s12915-022-01451-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Accepted: 10/27/2022] [Indexed: 11/11/2022] Open
Abstract
Abstract
Background
Without the availability of disease-modifying drugs, there is an unmet therapeutic need for osteoarthritic patients. During osteoarthritis, the homeostasis of articular chondrocytes is dysregulated and a phenotypical transition called hypertrophy occurs, leading to cartilage degeneration. Targeting this phenotypic transition has emerged as a potential therapeutic strategy. Chondrocyte phenotype maintenance and switch are controlled by an intricate network of intracellular factors, each influenced by a myriad of feedback mechanisms, making it challenging to intuitively predict treatment outcomes, while in silico modeling can help unravel that complexity. In this study, we aim to develop a virtual articular chondrocyte to guide experiments in order to rationalize the identification of potential drug targets via screening of combination therapies through computational modeling and simulations.
Results
We developed a signal transduction network model using knowledge-based and data-driven (machine learning) modeling technologies. The in silico high-throughput screening of (pairwise) perturbations operated with that network model highlighted conditions potentially affecting the hypertrophic switch. A selection of promising combinations was further tested in a murine cell line and primary human chondrocytes, which notably highlighted a previously unreported synergistic effect between the protein kinase A and the fibroblast growth factor receptor 1.
Conclusions
Here, we provide a virtual articular chondrocyte in the form of a signal transduction interactive knowledge base and of an executable computational model. Our in silico-in vitro strategy opens new routes for developing osteoarthritis targeting therapies by refining the early stages of drug target discovery.
Graphical Abstract
Collapse
|
8
|
Kearney CM, Khatab S, van Buul GM, Plomp SGM, Korthagen NM, Labberté MC, Goodrich LR, Kisiday JD, Van Weeren PR, van Osch GJVM, Brama PAJ. Treatment Effects of Intra-Articular Allogenic Mesenchymal Stem Cell Secretome in an Equine Model of Joint Inflammation. Front Vet Sci 2022; 9:907616. [PMID: 35812845 PMCID: PMC9257274 DOI: 10.3389/fvets.2022.907616] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2022] [Accepted: 05/20/2022] [Indexed: 11/13/2022] Open
Abstract
BackgroundAllogenic mesenchymal stem cell (MSC) secretome is a novel intra-articular therapeutic that has shown promise in in vitro and small animal models and warrants further investigation.ObjectivesTo investigate if intra-articular allogenic MSC-secretome has anti-inflammatory effects using an equine model of joint inflammation.Study DesignRandomized positively and negatively controlled experimental study.MethodIn phase 1, joint inflammation was induced bilaterally in radiocarpal joints of eight horses by injecting 0.25 ng lipopolysaccharide (LPS). After 2 h, the secretome of INFy and TNFα stimulated allogeneic equine MSCs was injected in one randomly assigned joint, while the contralateral joint was injected with medium (negative control). Clinical parameters (composite welfare scores, joint effusion, joint circumference) were recorded, and synovial fluid samples were analyzed for biomarkers (total protein, WBCC; eicosanoid mediators, CCL2; TNFα; MMP; GAGs; C2C; CPII) at fixed post-injection hours (PIH 0, 8, 24, 72, and 168 h). The effects of time and treatment on clinical and synovial fluid parameters and the presence of time-treatment interactions were evaluated. For phase 2, allogeneic MSC-secretome vs. allogeneic equine MSCs (positive control) was tested using a similar methodology.ResultsIn phase 1, the joint circumference was significantly (p < 0.05) lower in the MSC-secretome treated group compared to the medium control group at PIH 24, and significantly higher peak synovial GAG values were noted at PIH 24 (p < 0.001). In phase 2, no significant differences were noted between the treatment effects of MSC-secretome and MSCs.Main LimitationsThis study is a controlled experimental study and therefore cannot fully reflect natural joint disease. In phase 2, two therapeutics are directly compared and there is no negative control.ConclusionsIn this model of joint inflammation, intra-articular MSC-secretome injection had some clinical anti-inflammatory effects. An effect on cartilage metabolism, evident as a rise in GAG levels was also noted, although it is unclear whether this could be considered a beneficial or detrimental effect. When directly comparing MSC-secretome to MSCs in this model results were comparable, indicating that MSC-secretome could be a viable off-the-shelf alternative to MSC treatment.
Collapse
Affiliation(s)
- Clodagh M. Kearney
- School of Veterinary Medicine, University College Dublin, Dublin, Ireland
- *Correspondence: Clodagh M. Kearney
| | - Sohrab Khatab
- Department of Orthopaedics and Sports Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
| | - Gerben M. van Buul
- Department of Orthopaedics and Sports Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
- Beacon Hospital, Dublin, Ireland
| | - Saskia G. M. Plomp
- Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands
| | - Nicoline M. Korthagen
- Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands
| | - Margot C. Labberté
- School of Veterinary Medicine, University College Dublin, Dublin, Ireland
| | - Laurie R. Goodrich
- Equine Orthopaedic Research Center, Colorado State University, Fort Collins, CO, United States
| | - John D. Kisiday
- Equine Orthopaedic Research Center, Colorado State University, Fort Collins, CO, United States
| | - P. R. Van Weeren
- Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands
| | - Gerjo J. V. M. van Osch
- Department of Orthopaedics and Sports Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
- Department of Otorhinolaryngology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
| | - Pieter A. J. Brama
- School of Veterinary Medicine, University College Dublin, Dublin, Ireland
| |
Collapse
|
9
|
Siverino C, Fahmy-Garcia S, Mumcuoglu D, Oberwinkler H, Muehlemann M, Mueller T, Farrell E, van Osch GJVM, Nickel J. Site-Directed Immobilization of an Engineered Bone Morphogenetic Protein 2 (BMP2) Variant to Collagen-Based Microspheres Induces Bone Formation In Vivo. Int J Mol Sci 2022; 23:ijms23073928. [PMID: 35409290 PMCID: PMC8999711 DOI: 10.3390/ijms23073928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2022] [Revised: 03/21/2022] [Accepted: 03/29/2022] [Indexed: 11/26/2022] Open
Abstract
For the treatment of large bone defects, the commonly used technique of autologous bone grafting presents several drawbacks and limitations. With the discovery of the bone-inducing capabilities of bone morphogenetic protein 2 (BMP2), several delivery techniques were developed and translated to clinical applications. Implantation of scaffolds containing adsorbed BMP2 showed promising results. However, off-label use of this protein-scaffold combination caused severe complications due to an uncontrolled release of the growth factor, which has to be applied in supraphysiological doses in order to induce bone formation. Here, we propose an alternative strategy that focuses on the covalent immobilization of an engineered BMP2 variant to biocompatible scaffolds. The new BMP2 variant harbors an artificial amino acid with a specific functional group, allowing a site-directed covalent scaffold functionalization. The introduced artificial amino acid does not alter BMP2′s bioactivity in vitro. When applied in vivo, the covalently coupled BMP2 variant induces the formation of bone tissue characterized by a structurally different morphology compared to that induced by the same scaffold containing ab-/adsorbed wild-type BMP2. Our results clearly show that this innovative technique comprises translational potential for the development of novel osteoinductive materials, improving safety for patients and reducing costs.
Collapse
Affiliation(s)
- Claudia Siverino
- Department of Tissue Engineering and Regenerative Medicine, University Hospital Wuerzburg, 97070 Wuerzburg, Germany; (C.S.); (H.O.); (M.M.)
| | - Shorouk Fahmy-Garcia
- Department of Orthopaedics and Sports Medicine, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands; (S.F.-G.); (D.M.); (G.J.V.M.v.O.)
- Department of Internal Medicine, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands
- Department of Oral and Maxillofacial Surgery, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands;
| | - Didem Mumcuoglu
- Department of Orthopaedics and Sports Medicine, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands; (S.F.-G.); (D.M.); (G.J.V.M.v.O.)
- Fujifilm Manufacturing Europe B.V., 5047 TK Tilburg, The Netherlands
| | - Heike Oberwinkler
- Department of Tissue Engineering and Regenerative Medicine, University Hospital Wuerzburg, 97070 Wuerzburg, Germany; (C.S.); (H.O.); (M.M.)
| | - Markus Muehlemann
- Department of Tissue Engineering and Regenerative Medicine, University Hospital Wuerzburg, 97070 Wuerzburg, Germany; (C.S.); (H.O.); (M.M.)
| | - Thomas Mueller
- Department for Molecular Plant Physiology and Biophysics, Julius-von-Sachs Institute of the University Wuerzburg, 97082 Wuerzburg, Germany;
| | - Eric Farrell
- Department of Oral and Maxillofacial Surgery, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands;
| | - Gerjo J. V. M. van Osch
- Department of Orthopaedics and Sports Medicine, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands; (S.F.-G.); (D.M.); (G.J.V.M.v.O.)
- Department of Otorhinolaryngology, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands
| | - Joachim Nickel
- Department of Tissue Engineering and Regenerative Medicine, University Hospital Wuerzburg, 97070 Wuerzburg, Germany; (C.S.); (H.O.); (M.M.)
- Fraunhofer ISC, Translational Center RT, 97070 Wuerzburg, Germany
- Correspondence: ; Tel.: +49-0931-3184122
| |
Collapse
|
10
|
Lehmann J, Narcisi R, Franceschini N, Chatzivasileiou D, Boer CG, Koevoet WJLM, Putavet D, Drabek D, van Haperen R, de Keizer PLJ, van Osch GJVM, Ten Berge D. WNT/beta-catenin signalling interrupts a senescence-induction cascade in human mesenchymal stem cells that restricts their expansion. Cell Mol Life Sci 2022; 79:82. [PMID: 35048158 PMCID: PMC8770385 DOI: 10.1007/s00018-021-04035-x] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2021] [Revised: 10/18/2021] [Accepted: 11/09/2021] [Indexed: 12/23/2022]
Abstract
Senescence, the irreversible cell cycle arrest of damaged cells, is accompanied by a deleterious pro-inflammatory senescence-associated secretory phenotype (SASP). Senescence and the SASP are major factors in aging, cancer, and degenerative diseases, and interfere with the expansion of adult cells in vitro, yet little is known about how to counteract their induction and deleterious effects. Paracrine signals are increasingly recognized as important senescence triggers and understanding their regulation and mode of action may provide novel opportunities to reduce senescence-induced inflammation and improve cell-based therapies. Here, we show that the signalling protein WNT3A counteracts the induction of paracrine senescence in cultured human adult mesenchymal stem cells (MSCs). We find that entry into senescence in a small subpopulation of MSCs triggers a secretome that causes a feed-forward signalling cascade that with increasing speed induces healthy cells into senescence. WNT signals interrupt this cascade by repressing cytokines that mediate this induction of senescence. Inhibition of those mediators by interference with NF-κB or interleukin 6 signalling reduced paracrine senescence in absence of WNT3A and promoted the expansion of MSCs. Our work reveals how WNT signals can antagonize senescence and has relevance not only for expansion of adult cells but can also provide new insights into senescence-associated inflammatory and degenerative diseases.
Collapse
Affiliation(s)
- Johannes Lehmann
- Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.,Department of Cell Biology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.,Center for Molecular Medicine, Section Molecular Cancer Research, Division LAB, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Roberto Narcisi
- Department of Orthopaedics and Sports Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | - Natasja Franceschini
- Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | - Danai Chatzivasileiou
- Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | - Cindy G Boer
- Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | - Wendy J L M Koevoet
- Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | - Diana Putavet
- Center for Molecular Medicine, Section Molecular Cancer Research, Division LAB, University Medical Center Utrecht, Utrecht, The Netherlands.,Department of Genetics, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | - Dubravka Drabek
- Department of Cell Biology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.,Harbour Biomed, Rotterdam, the Netherlands
| | - Rien van Haperen
- Department of Cell Biology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.,Harbour Biomed, Rotterdam, the Netherlands
| | - Peter L J de Keizer
- Center for Molecular Medicine, Section Molecular Cancer Research, Division LAB, University Medical Center Utrecht, Utrecht, The Netherlands.,Department of Genetics, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | - Gerjo J V M van Osch
- Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.,Department of Orthopaedics and Sports Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | - Derk Ten Berge
- Department of Cell Biology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
| |
Collapse
|
11
|
Ferrao Blanco MN, Bastiaansen Jenniskens YM, Kops N, Chavli A, Narcisi R, Botter SM, Leenen PJM, van Osch GJVM, Fahy N. Intra-articular injection of triamcinolone acetonide sustains macrophage levels and aggravates osteophytosis during degenerative joint disease in mice. Br J Pharmacol 2021; 179:2771-2784. [PMID: 34907535 PMCID: PMC9305889 DOI: 10.1111/bph.15780] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2021] [Revised: 11/03/2021] [Accepted: 11/27/2021] [Indexed: 12/01/2022] Open
Abstract
BACKGROUND AND PURPOSE Corticosteroids such as triamcinolone acetonide (TAA) are potent drugs administered intra-articularly as an anti-inflammatory therapy to relieve pain associated with osteoarthritis (OA). However, the ability of early TAA intervention to mitigate OA progression and modulate immune cell subsets remains unclear. Here we sought to understand the effect of early intra-articular injection of TAA towards OA progression, local macrophages and peripheral blood monocytes. EXPERIMENTAL APPROACH Degenerative joint disease was induced by intra-articular injection of collagenase into the knee joint of C57BL/6 mice. After one week, TAA or saline was injected intra-articularly. Blood was taken throughout the study to analyse monocyte subsets. Mice were euthanised at day 14 and 56 post-induction of collagenase-induced OA (CiOA) to examine synovial macrophages and structural OA features. KEY RESULTS The percentage of macrophages relative to total live cells present within knee joints was increased in collagenase- compared to saline-injected knees at day 14 and was not altered by TAA treatment. However, at day 56 post-induction of CiOA TAA-treated knees had increased levels of macrophages compared with the knees of untreated CiOA-mice. The distribution of monocyte subsets present in peripheral blood was not altered by TAA treatment during the development of CiOA. Osteophyte maturation was increased in TAA-injected knees at day 56. CONCLUSION AND IMPLICATIONS Intra-articular injection of TAA increases long-term synovial macrophage numbers and osteophytosis. Our findings suggest that TAA accentuates the progression of osteoarthritis-associated features when applied to an acutely inflamed knee.
Collapse
Affiliation(s)
- Mauricio N Ferrao Blanco
- Department of Orthopaedics and Sports Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | | | - Nicole Kops
- Department of Orthopaedics and Sports Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Athina Chavli
- Department of Orthopaedics and Sports Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Roberto Narcisi
- Department of Orthopaedics and Sports Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Sander M Botter
- Swiss Center for Musculoskeletal Biobanking, Balgrist Campus AG, Zürich, Switzerland
| | - Pieter J M Leenen
- Department of Immunology, Erasmus MC, University Medical Center Rotterdam, The Netherlands
| | - Gerjo J V M van Osch
- Department of Orthopaedics and Sports Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.,Department of Otorhinolaryngology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.,Department of Biomechanical Engineering, University of Technology Delft, Delft, The Netherlands
| | - Niamh Fahy
- Department of Orthopaedics and Sports Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.,Department of Oral and Maxillofacial Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| |
Collapse
|
12
|
Muntz I, Fenu M, van Osch GJVM, Koenderink G. The role of cell-matrix interactions in connective tissue mechanics. Phys Biol 2021; 19. [PMID: 34902848 DOI: 10.1088/1478-3975/ac42b8] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Accepted: 12/13/2021] [Indexed: 11/12/2022]
Abstract
Living tissue is able to withstand large stresses in everyday life, yet it also actively adapts to dynamic loads. This remarkable mechanical behaviour emerges from the interplay between living cells and their non-living extracellular environment. Here we review recent insights into the biophysical mechanisms involved in the reciprocal interplay between cells and the extracellular matrix and how this interplay determines tissue mechanics, with a focus on connective tissues. We first describe the roles of the main macromolecular components of the extracellular matrix in regards to tissue mechanics. We then proceed to highlight the main routes via which cells sense and respond to their biochemical and mechanical extracellular environment. Next we introduce the three main routes via which cells can modify their extracellular environment: exertion of contractile forces, secretion and deposition of matrix components, and matrix degradation. Finally we discuss how recent insights in the mechanobiology of cell-matrix interactions are furthering our understanding of the pathophysiology of connective tissue diseases and cancer, and facilitating the design of novel strategies for tissue engineering.
Collapse
Affiliation(s)
- Iain Muntz
- Bionanoscience, TU Delft, Kavli Institute of Nanoscience Delft, Delft University of Technology, Van der Maasweg 9, Delft, Zuid-Holland, 2629 HC, NETHERLANDS
| | - Michele Fenu
- Otorhinolaryngology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Zuid-Holland, 3000 CA, NETHERLANDS
| | - Gerjo J V M van Osch
- Orthopaedics; Otorhinolaryngology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Zuid-Holland, 3000 CA, NETHERLANDS
| | - Gijsje Koenderink
- Bionanoscience, TU Delft, Kavli Institute of Nanoscience Delft, Delft University of Technology, Van der Maasweg 9, Delft, Zuid-Holland, 2629 HZ, NETHERLANDS
| |
Collapse
|
13
|
Rathnayake MSB, Farrugia BL, Kulakova K, ter Voert CEM, van Osch GJVM, Stok KS. Macromolecular Interactions in Cartilage Extracellular Matrix Vary According to the Cartilage Type and Location. Cartilage 2021; 13:476S-485S. [PMID: 33749320 PMCID: PMC8804747 DOI: 10.1177/19476035211000811] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE To investigate GAG-ECM (glycosaminoglycan-extracellular matrix) interactions in different cartilage types. To achieve this, we first aimed to determine protocols for consistent calculation of GAG content between cartilage types. DESIGN Auricular cartilage containing both collagen and elastin was used to determine the effect of lyophilization on GAG depletion activity. Bovine articular, auricular, meniscal, and nasal cartilage plugs were treated using different reagents to selectively remove GAGs. Sulfated glycosaminoglycan (sGAG) remaining in the sample after treatment were measured, and sGAG loss was compared between cartilage types. RESULTS The results indicate that dry weight of cartilage should be measured prior to cartilage treatment in order to provide a more accurate reference for normalization. Articular, meniscal, and nasal cartilage lost significant amounts of sGAG for all reagents used. However, only hyaluronidase was able to remove significant amount of sGAG from auricular cartilage. Furthermore, hyaluronidase was able to remove over 99% of sGAG from all cartilage types except auricular cartilage where it only removed around 76% of sGAG. The results indicate GAG-specific ECM binding for different cartilage types and locations. CONCLUSIONS In conclusion, lyophilization can be performed to determine native dry weight for normalization without affecting the degree of GAG treatment. To our knowledge, this is the first study to compare GAG-ECM interactions of different cartilage types using different GAG extraction methods. Degree of GAG depletion not only varied with cartilage type but also the same type from different anatomic locations. This suggests specific structure-function roles for GAG populations found in the tissues.
Collapse
Affiliation(s)
- Manula S. B. Rathnayake
- Department of Biomedical Engineering,
University of Melbourne, Parkville, Victoria, Australia
| | - Brooke L. Farrugia
- Department of Biomedical Engineering,
University of Melbourne, Parkville, Victoria, Australia
| | - Karyna Kulakova
- Department of Biomedical Engineering,
University of Melbourne, Parkville, Victoria, Australia
| | - Colet E. M. ter Voert
- Department of Biomedical Engineering,
University of Melbourne, Parkville, Victoria, Australia
| | - Gerjo J. V. M. van Osch
- Department of Otorhinolaryngology and
Department of Orthopaedics, Erasmus MC, University Medical Centre, Rotterdam, the
Netherlands
- Department of Biomedical Engineering, Faculty
of Mechanical, Maritime, and Materials Engineering, Delft University of Technology, Delft,
the Netherlands
| | - Kathryn S. Stok
- Department of Biomedical Engineering,
University of Melbourne, Parkville, Victoria, Australia
- Kathryn S. Stok, Department of Biomedical
Engineering, University of Melbourne, 203 Bouverie St, Carlton, Victoria 3053, Australia.
| |
Collapse
|
14
|
Utomo L, Fahy N, Kops N, van Tiel ST, Waarsing J, Verhaar JAN, Leenen PJM, van Osch GJVM, Bastiaansen‐Jenniskens YM. Macrophage phenotypes and monocyte subsets after destabilization of the medial meniscus in mice. J Orthop Res 2021; 39:2270-2280. [PMID: 33336820 PMCID: PMC8518591 DOI: 10.1002/jor.24958] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/09/2019] [Revised: 11/10/2020] [Accepted: 12/14/2020] [Indexed: 02/04/2023]
Abstract
Macrophages play an important role in the development and progression of osteoarthritis (OA). The aim of this study was to identify macrophage phenotypes in synovium and monocyte subsets in peripheral blood in C57BL/6 mice by destabilizing the medial meniscus (DMM), and the association of macrophage subsets with OA features. DMM, sham, and non-operated knees were histologically assessed between 1 and 56 days for macrophage polarization states by immunohistochemistry (IHC), cartilage damage, synovial thickening, and osteophytes (n = 9 per timepoint). Naive knees (n = 6) were used as controls. Monocyte and polarized synovial macrophage subsets were evaluated by flow cytometry. CD64 and CD206 levels on IHC were higher at early timepoints in DMM and sham knees compared to naive knees. iNOS labeling intensity was higher in DMM and sham knees than in naive knees from d3 onwards. CD163 expression was unaltered at all timepoints. Even though macrophage polarization profiles were similar in DMM and sham knees, only in DMM knees the presence of iNOS and CD206 associated with synovial thickness, and CD163 staining inversely correlated with osteophyte presence. At day 14, monocyte subset distribution was different in peripheral blood of DMM mice compared with sham mice. In conclusion, monocyte subsets in blood and synovial macrophage phenotypes vary after joint surgery. High levels of iNOS+ , CD163+ , and CD206+ cells are found in both destabilized and sham-operated knees, and coexistence with joint instability may be a requirement to initiate and exacerbate OA progression.
Collapse
Affiliation(s)
- Lizette Utomo
- Department of Orthopaedics, Erasmus MCUniversity Medical Center RotterdamRotterdamThe Netherlands,Present address:
L. Utomo, Department of Oral and Maxillofacial Surgery & Special Dental Care, University Medical Center Utrecht, Department of Clinical Sciences, Faculty of Veterinary MedicineUtrecht UniversityUtrechtThe Netherlands
| | - Niamh Fahy
- Department of Orthopaedics, Erasmus MCUniversity Medical Center RotterdamRotterdamThe Netherlands,Department of Oral and Maxillofacial Surgery, Erasmus MCUniversity Medical Center RotterdamRotterdamThe Netherlands
| | - Nicole Kops
- Department of Orthopaedics, Erasmus MCUniversity Medical Center RotterdamRotterdamThe Netherlands
| | - Sandra T. van Tiel
- Department of Radiology and Nuclear Medicine, Erasmus MCUniversity Medical Center RotterdamRotterdamThe Netherlands
| | - Jan Waarsing
- Department of Orthopaedics, Erasmus MCUniversity Medical Center RotterdamRotterdamThe Netherlands
| | - Jan A. N. Verhaar
- Department of Orthopaedics, Erasmus MCUniversity Medical Center RotterdamRotterdamThe Netherlands
| | - Pieter J. M. Leenen
- Department of Immunology, Erasmus MCUniversity Medical Center RotterdamThe Netherlands
| | - Gerjo J. V. M. van Osch
- Department of Orthopaedics, Erasmus MCUniversity Medical Center RotterdamRotterdamThe Netherlands,Department of Otorhinolaryngology, Erasmus MCUniversity Medical Center RotterdamRotterdamThe Netherlands
| | | |
Collapse
|
15
|
Oieni J, Lolli A, D'Atri D, Kops N, Yayon A, van Osch GJVM, Machluf M. Nano-ghosts: Novel biomimetic nano-vesicles for the delivery of antisense oligonucleotides. J Control Release 2021; 333:28-40. [PMID: 33741386 DOI: 10.1016/j.jconrel.2021.03.018] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2020] [Revised: 03/08/2021] [Accepted: 03/12/2021] [Indexed: 12/18/2022]
Abstract
Antisense oligonucleotides (ASOs) carry an enormous therapeutic potential in different research areas, however, the lack of appropriate carriers for their delivery to the target tissues is hampering their clinical translation. The present study investigates the application of novel biomimetic nano-vesicles, Nano-Ghosts (NGs), for the delivery of ASOs to human mesenchymal stem cells (MSCs), using a microRNA inhibitor (antimiR) against miR-221 as proof-of-concept. The integration of this approach with a hyaluronic acid-fibrin (HA-FB) hydrogel scaffold is also studied, thus expanding the potential of NGs applications in regenerative medicine. The study shows robust antimiR encapsulation in the NGs using electroporation and the NGs ability to be internalized in MSCs and to deliver their cargo while avoiding endo-lysosomal degradation. This leads to rapid and strong knock-down of miR-221 in hMSCs in vitro, both in 2D and 3D hydrogel culture conditions (>90% and > 80% silencing efficiency, respectively). Finally, in vivo studies performed with an osteochondral defect model demonstrate the NGs ability to effectively deliver antimiR to endogenous cells. Altogether, these results prove that the NGs can operate as stand-alone system or as integrated platform in combination with scaffolds for the delivery of ASOs for a wide range of applications in drug delivery and regenerative medicine.
Collapse
Affiliation(s)
- Jacopo Oieni
- Department of Biotechnology and Food Engineering, Technion - Israel Institute of Technology, Haifa 32000, Israel
| | - Andrea Lolli
- Department of Orthopaedics, Erasmus MC, University Medical Center, Rotterdam 3015GD, the Netherlands; Department of Oral and Maxillofacial Surgery, Erasmus MC, University Medical Center, Rotterdam 3015GD, the Netherlands
| | - Domenico D'Atri
- Department of Biotechnology and Food Engineering, Technion - Israel Institute of Technology, Haifa 32000, Israel
| | - Nicole Kops
- Department of Orthopaedics, Erasmus MC, University Medical Center, Rotterdam 3015GD, the Netherlands
| | - Avner Yayon
- Procore Ltd., Weizmann Science Park, 7 Golda Meir St., Ness Ziona 7414002, Israel
| | - Gerjo J V M van Osch
- Department of Orthopaedics, Erasmus MC, University Medical Center, Rotterdam 3015GD, the Netherlands; Department of Otorhinolaryngology, Head and Neck Surgery, Erasmus MC, University Medical Center, Rotterdam, 3015GD, the Netherlands; Department of Biomechanical Engineering, Faculty of Mechanical, Maritime, and Materials Engineering, Delft University of Technology, 2628, the Netherlands
| | - Marcelle Machluf
- Department of Biotechnology and Food Engineering, Technion - Israel Institute of Technology, Haifa 32000, Israel.
| |
Collapse
|
16
|
Vainieri ML, Alini M, Yayon A, van Osch GJVM, Grad S. Mechanical Stress Inhibits Early Stages of Endogenous Cell Migration: A Pilot Study in an Ex Vivo Osteochondral Model. Polymers (Basel) 2020; 12:polym12081754. [PMID: 32781503 PMCID: PMC7466115 DOI: 10.3390/polym12081754] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2020] [Revised: 07/25/2020] [Accepted: 08/03/2020] [Indexed: 01/07/2023] Open
Abstract
Cell migration has a central role in osteochondral defect repair initiation and biomaterial-mediated regeneration. New advancements to reestablish tissue function include biomaterials and factors promoting cell recruitment, differentiation and tissue integration, but little is known about responses to mechanical stimuli. In the present pilot study, we tested the influence of extrinsic forces in combination with biomaterials releasing chemoattractant signals on cell migration. We used an ex vivo mechanically stimulated osteochondral defect explant filled with fibrin/hyaluronan hydrogel, in presence or absence of platelet-derived growth factor-BB or stromal cell-derived factor 1, to assess endogenous cell recruitment into the wound site. Periodic mechanical stress at early time point negatively influenced cell infiltration compared to unloaded samples, and the implementation of chemokines to increase cell migration was not efficient to overcome this negative effect. The gene expression at 15 days of culture indicated a marked downregulation of matrix metalloproteinase (MMP)13 and MMP3, a decrease of β1 integrin and increased mRNA levels of actin in osteochondral samples exposed to complex load. This work using an ex vivo osteochondral mechanically stimulated advanced platform demonstrated that recurrent mechanical stress at early time points impeded cell migration into the hydrogel, providing a unique opportunity to improve our understanding on management of joint injury.
Collapse
Affiliation(s)
- Maria L. Vainieri
- AO Research Institute Davos, 7270 Davos, Switzerland; (M.L.V.); (M.A.)
- Department of Orthopaedics, Erasmus MC, University Medical Center Rotterdam, 3015 CN Rotterdam, The Netherlands;
| | - Mauro Alini
- AO Research Institute Davos, 7270 Davos, Switzerland; (M.L.V.); (M.A.)
| | - Avner Yayon
- ProCore Ltd., Weizmann Science Park, 7 Golda Meir St., Ness Ziona 70400, Israel;
| | - Gerjo J. V. M. van Osch
- Department of Orthopaedics, Erasmus MC, University Medical Center Rotterdam, 3015 CN Rotterdam, The Netherlands;
- Department of Otorhinolaryngology, Erasmus MC, University Medical Center Rotterdam, 3015 CN Rotterdam, The Netherlands
- Department of Biomedical Engineering, University of Technology Delft, 2628 CD Delft, The Netherlands
| | - Sibylle Grad
- AO Research Institute Davos, 7270 Davos, Switzerland; (M.L.V.); (M.A.)
- Department of Health Sciences and Technology, ETH Zurich, 8092 Zurich, Switzerland
- Correspondence: ; Tel.: +41-81-4142480
| |
Collapse
|
17
|
Voskamp C, Koevoet WJLM, Somoza RA, Caplan AI, Lefebvre V, van Osch GJVM, Narcisi R. Enhanced Chondrogenic Capacity of Mesenchymal Stem Cells After TNFα Pre-treatment. Front Bioeng Biotechnol 2020; 8:658. [PMID: 32714905 PMCID: PMC7344141 DOI: 10.3389/fbioe.2020.00658] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2020] [Accepted: 05/27/2020] [Indexed: 01/14/2023] Open
Abstract
Mesenchymal stem cells (MSCs) are promising cells to treat cartilage defects due to their chondrogenic differentiation potential. However, an inflammatory environment during differentiation, such as the presence of the cytokine TNFα, inhibits chondrogenesis and limits the clinical use of MSCs. On the other hand, it has been reported that exposure to TNFα during in vitro expansion can increase proliferation, migration, and the osteogenic capacity of MSCs and therefore can be beneficial for tissue regeneration. This indicates that the role of TNFα on MSCs may be dependent on the differentiation stage. To improve the chondrogenic capacity of MSCs in the presence of an inflamed environment, we aimed to determine the effect of TNFα on the chondrogenic differentiation capacity of MSCs. Here, we report that TNFα exposure during MSC expansion increased the chondrogenic differentiation capacity regardless of the presence of TNFα during chondrogenesis and that this effect of TNFα during expansion was reversed upon TNFα withdrawal. Interestingly, pre-treatment with another pro-inflammatory cytokine, IL-1β, did not increase the chondrogenic capacity of MSCs indicating that the pro-chondrogenic effect is specific for TNFα. Finally, we show that TNFα pre-treatment increased the levels of SOX11 and active β-catenin suggesting that these intracellular effectors may be useful targets to improve MSC-based cartilage repair. Overall, these results suggest that TNFα pre-treatment, by modulating SOX11 levels and WNT/β-catenin signaling, could be used as a strategy to improve MSC-based cartilage repair.
Collapse
Affiliation(s)
- Chantal Voskamp
- Department of Orthopaedics, Erasmus MC, University Medical Center, Rotterdam, Netherlands
| | - Wendy J L M Koevoet
- Department of Otorhinolaryngology, Erasmus MC, University Medical Center, Rotterdam, Netherlands
| | - Rodrigo A Somoza
- Department of Biology and Skeletal Research Center, Case Western Reserve University, Cleveland, OH, United States
| | - Arnold I Caplan
- Department of Biology and Skeletal Research Center, Case Western Reserve University, Cleveland, OH, United States
| | - Véronique Lefebvre
- Division of Orthopedic Surgery, Department of Surgery, Children's Hospital of Philadelphia, Philadelphia, PA, United States
| | - Gerjo J V M van Osch
- Department of Orthopaedics, Erasmus MC, University Medical Center, Rotterdam, Netherlands.,Department of Otorhinolaryngology, Erasmus MC, University Medical Center, Rotterdam, Netherlands
| | - Roberto Narcisi
- Department of Orthopaedics, Erasmus MC, University Medical Center, Rotterdam, Netherlands
| |
Collapse
|
18
|
Khatab S, Leijs MJ, van Buul G, Haeck J, Kops N, Nieboer M, Bos PK, Verhaar JAN, Bernsen M, van Osch GJVM. MSC encapsulation in alginate microcapsules prolongs survival after intra-articular injection, a longitudinal in vivo cell and bead integrity tracking study. Cell Biol Toxicol 2020; 36:553-570. [PMID: 32474743 PMCID: PMC7661423 DOI: 10.1007/s10565-020-09532-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2019] [Accepted: 04/29/2020] [Indexed: 02/06/2023]
Abstract
Mesenchymal stem cells (MSC) are promising candidates for use as a biological therapeutic. Since locally injected MSC disappear within a few weeks, we hypothesize that efficacy of MSC can be enhanced by prolonging their presence. Previously, encapsulation in alginate was suggested as a suitable approach for this purpose. We found no differences between the two alginate types, alginate high in mannuronic acid (High M) and alginate high in guluronic acid (High G), regarding MSC viability, MSC immunomodulatory capability, or retention of capsule integrity after subcutaneous implantation in immune competent rats. High G proved to be more suitable for production of injectable beads. Firefly luciferase-expressing rat MSC were used to track MSC viability. Encapsulation in high G alginate prolonged the presence of metabolically active allogenic MSC in immune competent rats with monoiodoacetate-induced osteoarthritis for at least 8 weeks. Encapsulation of human MSC for local treatment by intra-articular injection did not significantly influence the effect on pain, synovial inflammation, or cartilage damage in this disease model. MSC encapsulation in alginate allows for an injectable approach which prolongs the presence of viable cells subcutaneously or in an osteoarthritic joint. Further fine tuning of alginate formulation and effective dosage for might be required in order to improve therapeutic efficacy depending on the target disease. Graphical Abstract ![]()
Collapse
Affiliation(s)
- Sohrab Khatab
- Department of Orthopaedics, Erasmus MC University Medical Center Rotterdam, Wytemaweg 80, 3015, CN, Rotterdam, the Netherlands
- Department of Radiology and Nuclear Medicine, Erasmus MC University Medical Center Rotterdam, Wytemaweg 80, 3015, CN, Rotterdam, the Netherlands
| | - Maarten J Leijs
- Department of Orthopaedics, Erasmus MC University Medical Center Rotterdam, Wytemaweg 80, 3015, CN, Rotterdam, the Netherlands
- Department of Radiology and Nuclear Medicine, Erasmus MC University Medical Center Rotterdam, Wytemaweg 80, 3015, CN, Rotterdam, the Netherlands
| | - Gerben van Buul
- Department of Orthopaedics, Erasmus MC University Medical Center Rotterdam, Wytemaweg 80, 3015, CN, Rotterdam, the Netherlands
| | - Joost Haeck
- Department of Radiology and Nuclear Medicine, Erasmus MC University Medical Center Rotterdam, Wytemaweg 80, 3015, CN, Rotterdam, the Netherlands
| | - Nicole Kops
- Department of Orthopaedics, Erasmus MC University Medical Center Rotterdam, Wytemaweg 80, 3015, CN, Rotterdam, the Netherlands
| | - Michael Nieboer
- Department of Orthopaedics, Erasmus MC University Medical Center Rotterdam, Wytemaweg 80, 3015, CN, Rotterdam, the Netherlands
| | - P Koen Bos
- Department of Orthopaedics, Erasmus MC University Medical Center Rotterdam, Wytemaweg 80, 3015, CN, Rotterdam, the Netherlands
| | - Jan A N Verhaar
- Department of Orthopaedics, Erasmus MC University Medical Center Rotterdam, Wytemaweg 80, 3015, CN, Rotterdam, the Netherlands
| | - Monique Bernsen
- Department of Radiology and Nuclear Medicine, Erasmus MC University Medical Center Rotterdam, Wytemaweg 80, 3015, CN, Rotterdam, the Netherlands
| | - Gerjo J V M van Osch
- Department of Orthopaedics, Erasmus MC University Medical Center Rotterdam, Wytemaweg 80, 3015, CN, Rotterdam, the Netherlands.
- Department of Otorhinolaryngology, Erasmus MC University Medical Center Rotterdam, Wytemaweg 80, 3015, CN, Rotterdam, the Netherlands.
| |
Collapse
|
19
|
Nossin Y, Farrell E, Koevoet WJLM, Somoza RA, Caplan AI, Brachvogel B, van Osch GJVM. Angiogenic Potential of Tissue Engineered Cartilage From Human Mesenchymal Stem Cells Is Modulated by Indian Hedgehog and Serpin E1. Front Bioeng Biotechnol 2020; 8:327. [PMID: 32363188 PMCID: PMC7180203 DOI: 10.3389/fbioe.2020.00327] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2019] [Accepted: 03/25/2020] [Indexed: 12/26/2022] Open
Abstract
With rising demand for cartilage tissue repair and replacement, the differentiation of mesenchymal stem cells (BMSCs) into cartilage tissue forming cells provides a promising solution. Often, the BMSC-derived cartilage does not remain stable and continues maturing to bone through the process of endochondral ossification in vivo. Similar to the growth plate, invasion of blood vessels is an early hallmark of endochondral ossification and a necessary step for completion of ossification. This invasion originates from preexisting vessels that expand via angiogenesis, induced by secreted factors produced by the cartilage graft. In this study, we aimed to identify factors secreted by chondrogenically differentiated bone marrow-derived human BMSCs to modulate angiogenesis. The secretome of chondrogenic pellets at day 21 of the differentiation program was collected and tested for angiogenic capacity using in vitro endothelial migration and proliferation assays as well as the chick chorioallantoic membrane (CAM) assay. Taken together, these assays confirmed the pro-angiogenic potential of the secretome. Putative secreted angiogenic factors present in this medium were identified by comparative global transcriptome analysis between murine growth plate cartilage, human chondrogenic BMSC pellets and human neonatal articular cartilage. We then verified by PCR eight candidate angiogenesis modulating factors secreted by differentiated BMSCs. Among those, Serpin E1 and Indian Hedgehog (IHH) had a higher level of expression in BMSC-derived cartilage compared to articular chondrocyte derived cartilage. To understand the role of these factors in the pro-angiogenic secretome, we used neutralizing antibodies to functionally block them in the conditioned medium. Here, we observed a 1.4-fold increase of endothelial cell proliferation when blocking IHH and 1.5-fold by Serpin E1 blocking compared to unblocked control conditioned medium. Furthermore, endothelial migration was increased 1.9-fold by Serpin E1 blocking and 2.7-fold by IHH blocking. This suggests that the pro-angiogenic potential of chondrogenically differentiated BMSC secretome could be further augmented through inhibition of specific factors such as IHH and Serpin E1 identified as anti-angiogenic factors.
Collapse
Affiliation(s)
- Yannick Nossin
- Department of Otorhinolaryngology, Head and Neck Surgery, Erasmus MC, University Medical Center, Rotterdam, Netherlands
| | - Eric Farrell
- Department of Oral and Maxillofacial Surgery, Erasmus MC, University Medical Center, Rotterdam, Netherlands
| | - Wendy J L M Koevoet
- Department of Otorhinolaryngology, Head and Neck Surgery, Erasmus MC, University Medical Center, Rotterdam, Netherlands
| | - Rodrigo A Somoza
- Department of Biology, Skeletal Research Center, Case Western Reserve University, Cleveland, OH, United States.,Center for Multimodal Evaluation of Engineered-Cartilage, Case Western Reserve University, Cleveland, OH, United States
| | - Arnold I Caplan
- Department of Biology, Skeletal Research Center, Case Western Reserve University, Cleveland, OH, United States.,Center for Multimodal Evaluation of Engineered-Cartilage, Case Western Reserve University, Cleveland, OH, United States
| | - Bent Brachvogel
- Department of Pediatrics and Adolescent Medicine, Experimental Neonatology, Faculty of Medicine, University of Cologne, Cologne, Germany.,Faculty of Medicine, Center for Biochemistry, University of Cologne, Cologne, Germany
| | - Gerjo J V M van Osch
- Department of Otorhinolaryngology, Head and Neck Surgery, Erasmus MC, University Medical Center, Rotterdam, Netherlands.,Department of Orthopedics, Erasmus MC, University Medical Center, Rotterdam, Netherlands
| |
Collapse
|
20
|
Voskamp C, van de Peppel J, Gasparini S, Giannoni P, van Leeuwen JPTM, van Osch GJVM, Narcisi R. Sorting living mesenchymal stem cells using a TWIST1 RNA-based probe depends on incubation time and uptake capacity. Cytotechnology 2019; 72:37-45. [PMID: 31728801 PMCID: PMC7002702 DOI: 10.1007/s10616-019-00355-w] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2019] [Accepted: 11/07/2019] [Indexed: 12/26/2022] Open
Abstract
Bone marrow derived mesenchymal stromal cells (BMSCs) are multipotent progenitors of particular interest for cell-based tissue engineering therapies. However, one disadvantage that limit their clinical use is their heterogeneity. In the last decades a great effort was made to select BMSC subpopulations based on cell surface markers, however there is still no general consensus on which markers to use to obtain the best BMSCs for tissue regeneration. Looking for alternatives we decided to focus on a probe-based method to detect intracellular mRNA in living cells, the SmartFlare technology. This technology does not require fixation of the cells and allows us to sort living cells based on gene expression into functionally different populations. However, since the technology is available it is debated whether the probes specifically recognize their target mRNAs. We validated the TWIST1 probe and demonstrated that it specifically recognizes TWIST1 in BMSCs. However, differences in probe concentration, incubation time and cellular uptake can strongly influence signal specificity. In addition we found that TWIST1high expressing cells have an increased expansion rate compared to TWIST1low expressing cells derived
from the same initial population of BMSCs. The SmartFlare probes recognize their target gene, however for each probe and cell type validation of the protocol is necessary.
Collapse
Affiliation(s)
- Chantal Voskamp
- Department of Orthopaedics, Erasmus MC, 3015 CN, Rotterdam, The Netherlands
| | | | - Simona Gasparini
- Department of Orthopaedics, Erasmus MC, 3015 CN, Rotterdam, The Netherlands.,Department of Experimental Medicine, University of Genova, Genoa, Italy
| | - Paolo Giannoni
- Department of Experimental Medicine, University of Genova, Genoa, Italy
| | | | - Gerjo J V M van Osch
- Department of Orthopaedics, Erasmus MC, 3015 CN, Rotterdam, The Netherlands.,Department of Otorhinolaryngology, Erasmus MC, 3015 CN, Rotterdam, The Netherlands
| | - Roberto Narcisi
- Department of Orthopaedics, Erasmus MC, 3015 CN, Rotterdam, The Netherlands.
| |
Collapse
|
21
|
Lolli A, Sivasubramaniyan K, Vainieri ML, Oieni J, Kops N, Yayon A, van Osch GJVM. Hydrogel-based delivery of antimiR-221 enhances cartilage regeneration by endogenous cells. J Control Release 2019; 309:220-230. [PMID: 31369767 DOI: 10.1016/j.jconrel.2019.07.040] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2019] [Revised: 06/15/2019] [Accepted: 07/28/2019] [Indexed: 02/06/2023]
Abstract
Articular cartilage is frequently injured by trauma or osteoarthritis, with limited and inadequate treatment options. We investigated a new strategy based on hydrogel-mediated delivery of a locked nucleic acid microRNA inhibitor targeting miR-221 (antimiR-221) to guide in situ cartilage repair by endogenous cells. First, we showed that transfection of antimiR-221 into human bone marrow-derived mesenchymal stromal cells (hMSCs) blocked miR-221 expression and enhanced chondrogenesis in vitro. Next, we loaded a fibrin/hyaluronan (FB/HA) hydrogel with antimiR-221 in combination or not with lipofectamine carrier. FB/HA strongly retained functional antimiR-221 over 14 days of in vitro culture, and provided a supportive environment for cell transfection, as validated by flow cytometry and qRT-PCR analysis. Seeding of hMSCs on the surface of antimiR-221 loaded FB/HA led to invasion of the hydrogel and miR-221 knockdown in situ within 7 days. Overall, the use of lipofectamine enhanced the potency of the system, with increased antimiR-221 retention and miR-221 silencing in infiltrating cells. Finally, FB/HA hydrogels were used to fill defects in osteochondral biopsies that were implanted subcutaneously in mice. FB/HA loaded with antimiR-221/lipofectamine significantly enhanced cartilage repair by endogenous cells, demonstrating the feasibility of our approach and the need to achieve highly effective in situ transfection. Our study provides new evidence on the treatment of focal cartilage injuries using controlled biomaterial-mediated delivery of antimicroRNA for in situ guided regeneration.
Collapse
Affiliation(s)
- Andrea Lolli
- Department of Orthopaedics, Erasmus MC, University Medical Center, Rotterdam, the Netherlands
| | | | - Maria L Vainieri
- Department of Orthopaedics, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; AO Research Institute, Davos, Switzerland
| | - Jacopo Oieni
- Faculty of Biotechnology and Food Engineering, Technion - Israel Institute of Technology, Haifa, Israel
| | - Nicole Kops
- Department of Orthopaedics, Erasmus MC, University Medical Center, Rotterdam, the Netherlands
| | - Avner Yayon
- ProCore Ltd., Weizmann Science Park, Nes Ziona, Israel
| | - Gerjo J V M van Osch
- Department of Orthopaedics, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; Department of Otorhinolaryngology, Head and Neck Surgery, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
| |
Collapse
|
22
|
Fahmy-Garcia S, Farrell E, Witte-Bouma J, Robbesom-van den Berge I, Suarez M, Mumcuoglu D, Walles H, Kluijtmans SGJM, van der Eerden BCJ, van Osch GJVM, van Leeuwen JPTM, van Driel M. Follistatin Effects in Migration, Vascularization, and Osteogenesis in vitro and Bone Repair in vivo. Front Bioeng Biotechnol 2019; 7:38. [PMID: 30881954 PMCID: PMC6405513 DOI: 10.3389/fbioe.2019.00038] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2018] [Accepted: 02/13/2019] [Indexed: 12/16/2022] Open
Abstract
The use of biomaterials and signaling molecules to induce bone formation is a promising approach in the field of bone tissue engineering. Follistatin (FST) is a glycoprotein able to bind irreversibly to activin A, a protein that has been reported to inhibit bone formation. We investigated the effect of FST in critical processes for bone repair, such as cell recruitment, osteogenesis and vascularization, and ultimately its use for bone tissue engineering. In vitro, FST promoted mesenchymal stem cell (MSC) and endothelial cell (EC) migration as well as essential steps in the formation and expansion of the vasculature such as EC tube-formation and sprouting. FST did not enhance osteogenic differentiation of MSCs, but increased committed osteoblast mineralization. In vivo, FST was loaded in an in situ gelling formulation made by alginate and recombinant collagen-based peptide microspheres and implanted in a rat calvarial defect model. Two FST variants (FST288 and FST315) with major differences in their affinity to cell-surface proteoglycans, which may influence their effect upon in vivo bone repair, were tested. In vitro, most of the loaded FST315 was released over 4 weeks, contrary to FST288, which was mostly retained in the biomaterial. However, none of the FST variants improved in vivo bone healing compared to control. These results demonstrate that FST enhances crucial processes needed for bone repair. Further studies need to investigate the optimal FST carrier for bone regeneration.
Collapse
Affiliation(s)
- Shorouk Fahmy-Garcia
- Department of Orthopedics, Erasmus MC, University Medical Center, Rotterdam, Netherlands.,Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, Netherlands
| | - Eric Farrell
- Department of Oral and Maxillofacial Surgery, Erasmus MC, University Medical Center, Rotterdam, Netherlands
| | - Janneke Witte-Bouma
- Department of Oral and Maxillofacial Surgery, Erasmus MC, University Medical Center, Rotterdam, Netherlands
| | | | - Melva Suarez
- Institute of Tissue Engineering and Regenerative Medicine, Julius-Maximillians University Würzburg, Würzburg, Germany
| | - Didem Mumcuoglu
- Department of Orthopedics, Erasmus MC, University Medical Center, Rotterdam, Netherlands.,Fujifilm Manufacturing Europe B.V., Tilburg, Netherlands
| | - Heike Walles
- Institute of Tissue Engineering and Regenerative Medicine, Julius-Maximillians University Würzburg, Würzburg, Germany
| | | | - Bram C J van der Eerden
- Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, Netherlands
| | - Gerjo J V M van Osch
- Department of Orthopedics, Erasmus MC, University Medical Center, Rotterdam, Netherlands.,Department of Otorhinolaryngology, Head and Neck Surgery, Erasmus MC, University Medical Center, Rotterdam, Netherlands
| | | | - Marjolein van Driel
- Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, Netherlands
| |
Collapse
|
23
|
Lolli A, Colella F, De Bari C, van Osch GJVM. Targeting anti-chondrogenic factors for the stimulation of chondrogenesis: A new paradigm in cartilage repair. J Orthop Res 2019; 37:12-22. [PMID: 30175861 DOI: 10.1002/jor.24136] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/25/2018] [Accepted: 08/09/2018] [Indexed: 02/04/2023]
Abstract
Trauma and age-related cartilage disorders represent a major global cause of morbidity, resulting in chronic pain and disability in patients. A lack of effective therapies, together with a rapidly aging population, creates an impressive clinical and economic burden on healthcare systems. In this scenario, experimental therapies based on transplantation or in situ stimulation of skeletal Mesenchymal Stem/progenitor Cells (MSCs) have raised great interest for cartilage repair. Nevertheless, the challenge of guiding MSC differentiation and preventing cartilage hypertrophy and calcification still needs to be overcome. While research has mostly focused on the stimulation of cartilage anabolism using growth factors, several issues remain unresolved prompting the field to search for novel solutions. Recently, inhibition of anti-chondrogenic regulators has emerged as an intriguing opportunity. Anti-chondrogenic regulators include extracellular proteins as well as intracellular transcription factors and microRNAs that act as potent inhibitors of pro-chondrogenic signals. Suppression of these inhibitors can enhance MSC chondrogenesis and production of cartilage matrix. We here review the current knowledge concerning different types of anti-chondrogenic regulators. We aim to highlight novel therapeutic targets for cartilage repair and discuss suitable tools for suppressing their anti-chondrogenic functions. Further effort is needed to unveil the therapeutic perspectives of this approach and pave the way for effective treatment of cartilage injuries in patients. © 2018 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res.
Collapse
Affiliation(s)
- Andrea Lolli
- Department of Orthopaedics, Erasmus MC, University Medical Center, Wytemaweg 80, 3015CN Rotterdam, the Netherlands
| | - Fabio Colella
- Arthritis and Regenerative Medicine Laboratory, Aberdeen Centre for Arthritis and Musculoskeletal Health, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom
| | - Cosimo De Bari
- Arthritis and Regenerative Medicine Laboratory, Aberdeen Centre for Arthritis and Musculoskeletal Health, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom
| | - Gerjo J V M van Osch
- Department of Orthopaedics, Erasmus MC, University Medical Center, Wytemaweg 80, 3015CN Rotterdam, the Netherlands.,Department of Otorhinolaryngology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands
| |
Collapse
|
24
|
Fahmy-Garcia S, Mumcuoglu D, de Miguel L, Dieleman V, Witte-Bouma J, van der Eerden BCJ, van Driel M, Eglin D, Verhaar JAN, Kluijtmans SGJM, van Osch GJVM, Farrell E. Novel In Situ Gelling Hydrogels Loaded with Recombinant Collagen Peptide Microspheres as a Slow-Release System Induce Ectopic Bone Formation. Adv Healthc Mater 2018; 7:e1801496. [PMID: 30565901 DOI: 10.1002/adhm.201801496] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
25
|
de Kroon LMG, van den Akker GGH, Brachvogel B, Narcisi R, Belluoccio D, Jenner F, Bateman JF, Little CB, Brama PAJ, Blaney Davidson EN, van der Kraan PM, van Osch GJVM. Identification of TGFβ-related genes regulated in murine osteoarthritis and chondrocyte hypertrophy by comparison of multiple microarray datasets. Bone 2018; 116:67-77. [PMID: 30010080 DOI: 10.1016/j.bone.2018.07.008] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/07/2017] [Revised: 07/10/2018] [Accepted: 07/11/2018] [Indexed: 01/04/2023]
Abstract
OBJECTIVE Osteoarthritis (OA) is a joint disease characterized by progressive degeneration of articular cartilage. Some features of OA, including chondrocyte hypertrophy and focal calcification of articular cartilage, resemble the endochondral ossification processes. Alterations in transforming growth factor β (TGFβ) signaling have been associated with OA as well as with chondrocyte hypertrophy. Our aim was to identify novel candidate genes implicated in chondrocyte hypertrophy during OA pathogenesis by determining which TGFβ-related genes are regulated during murine OA and endochondral ossification. METHODS A list of 580 TGFβ-related genes, including TGFβ signaling pathway components and TGFβ-target genes, was generated. Regulation of these TGFβ-related genes was assessed in a microarray of murine OA cartilage: 1, 2 and 6 weeks after destabilization of the medial meniscus (DMM). Subsequently, genes regulated in the DMM model were studied in two independent murine microarray datasets on endochondral ossification: the growth plate and transient embryonic cartilage (joint development). RESULTS A total of 106 TGFβ-related genes were differentially expressed in articular cartilage of DMM-operated mice compared to sham-control. From these genes, 43 were similarly regulated during chondrocyte hypertrophy in the growth plate or embryonic joint development. Among these 43 genes, 18 genes have already been associated with OA. The remaining 25 genes were considered as novel candidate genes involved in OA pathogenesis and endochondral ossification. In supplementary data of published human OA microarrays we found indications that 15 of the 25 novel genes are indeed regulated in articular cartilage of human OA patients. CONCLUSION By focusing on TGFβ-related genes during OA and chondrocyte hypertrophy in mice, we identified 18 known and 25 new candidate genes potentially implicated in phenotypical changes in chondrocytes leading to OA. We propose that 15 of these candidates warrant further investigation as therapeutic target for OA as they are also regulated in articular cartilage of OA patients.
Collapse
Affiliation(s)
- Laurie M G de Kroon
- Department of Rheumatology, Experimental Rheumatology, Radboud University Medical Center, Nijmegen, the Netherlands; Department of Orthopedics, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
| | - Guus G H van den Akker
- Department of Rheumatology, Experimental Rheumatology, Radboud University Medical Center, Nijmegen, the Netherlands.
| | - Bent Brachvogel
- Center for Biochemistry, Medical Faculty, University of Cologne, Cologne, Germany; Department of Pediatrics and Adolescent Medicine, Experimental Neonatology, Medical Faculty, University of Cologne, Cologne, Germany.
| | - Roberto Narcisi
- Department of Orthopedics, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
| | - Daniele Belluoccio
- Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia.
| | - Florien Jenner
- Equine University Hospital, University of Veterinary Medicine, Vienna, Austria.
| | - John F Bateman
- Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia.
| | - Christopher B Little
- Raymond Purves Bone and Joint Research Laboratories, Kolling Institute of Medical Research, University of Sydney, St Leonards, New South Wales, Australia.
| | - Pieter A J Brama
- Veterinary Clinical Sciences, School of Veterinary Medicine, University College Dublin, Dublin, Ireland.
| | - Esmeralda N Blaney Davidson
- Department of Rheumatology, Experimental Rheumatology, Radboud University Medical Center, Nijmegen, the Netherlands.
| | - Peter M van der Kraan
- Department of Rheumatology, Experimental Rheumatology, Radboud University Medical Center, Nijmegen, the Netherlands.
| | - Gerjo J V M van Osch
- Department of Orthopedics, Erasmus MC University Medical Center, Rotterdam, the Netherlands; Department of Otorhinolaryngology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
| |
Collapse
|
26
|
Fahmy-Garcia S, Mumcuoglu D, de Miguel L, Dieleman V, Witte-Bouma J, van der Eerden BCJ, van Driel M, Eglin D, Verhaar JAN, Kluijtmans SGJM, van Osch GJVM, Farrell E. Novel In Situ Gelling Hydrogels Loaded with Recombinant Collagen Peptide Microspheres as a Slow-Release System Induce Ectopic Bone Formation. Adv Healthc Mater 2018; 7:e1800507. [PMID: 30230271 DOI: 10.1002/adhm.201800507] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2018] [Indexed: 01/06/2023]
Abstract
New solutions for large bone defect repair are needed. Here, in situ gelling slow release systems for bone induction are assessed. Collagen-I based Recombinant Peptide (RCP) microspheres (MSs) are produced and used as a carrier for bone morphogenetic protein 2 (BMP-2). The RCP-MSs are dispersed in three hydrogels: high mannuronate (SLM) alginate, high guluronate (SLG) alginate, and thermoresponsive hyaluronan derivative (HApN). HApN+RCP-MS forms a gel structure at 32 ºC or above, while SLM+RCP-MS and SLG+RCP-MS respond to shear stress displaying thixotropic behavior. Alginate formulations show sustained release of BMP-2, while there is minimal release from HApN. These formulations are injected subcutaneously in rats. SLM+RCP-MS and SLG+RCP-MS loaded with BMP-2 induce ectopic bone formation as revealed by X-ray tomography and histology, whereas HApN+RCP-MS do not. Vascularization occurs within all the formulations studied and is significantly higher in SLG+MS and HApN+RCP-MS than in SLM+RCP-MS. Inflammation (based on macrophage subset staining) decreases over time in both alginate groups, but increases in the HApN+RCP-MS condition. It is shown that a balance between inflammatory cell infiltration, BMP-2 release, and vascularization, achieved in the SLG+RCP-MS alginate condition, is optimal for the induction of de novo bone formation.
Collapse
Affiliation(s)
- Shorouk Fahmy-Garcia
- Department of Orthopedics; Erasmus MC; Wytemaweg 80 3015CN Rotterdam The Netherlands
- Department of Internal Medicine; Erasmus MC; Wytemaweg 80 3015CN Rotterdam The Netherlands
| | - Didem Mumcuoglu
- Department of Orthopedics; Erasmus MC; Wytemaweg 80 3015CN Rotterdam The Netherlands
- Fujifilm Manufacturing Europe B.V.; Oudenstaart 1 5047TK Tilburg The Netherlands
| | - Laura de Miguel
- Fujifilm Manufacturing Europe B.V.; Oudenstaart 1 5047TK Tilburg The Netherlands
| | - Veerle Dieleman
- Department of Oral and Maxillofacial Surgery; Special Dental Care and Orthodontics; Erasmus MC; Wytemaweg 80 3015CN Rotterdam The Netherlands
| | - Janneke Witte-Bouma
- Department of Oral and Maxillofacial Surgery; Special Dental Care and Orthodontics; Erasmus MC; Wytemaweg 80 3015CN Rotterdam The Netherlands
| | | | - Marjolein van Driel
- Department of Internal Medicine; Erasmus MC; Wytemaweg 80 3015CN Rotterdam The Netherlands
| | - David Eglin
- AO Research Institute Davos; Clavadelerstrasse 8 7270 Davos Switzerland
| | - Jan A. N. Verhaar
- Department of Orthopedics; Erasmus MC; Wytemaweg 80 3015CN Rotterdam The Netherlands
| | | | - Gerjo J. V. M. van Osch
- Department of Orthopedics; Erasmus MC; Wytemaweg 80 3015CN Rotterdam The Netherlands
- Department of Otorhinolaryngology; Head and Neck Surgery; Erasmus MC; Wytemaweg 80 3015CN Rotterdam The Netherlands
| | - Eric Farrell
- Department of Oral and Maxillofacial Surgery; Special Dental Care and Orthodontics; Erasmus MC; Wytemaweg 80 3015CN Rotterdam The Netherlands
| |
Collapse
|
27
|
Utomo L, Eijgenraam SM, Meuffels DE, Bierma‐Zeinstra SMA, Bastiaansen‐Jenniskens YM, van Osch GJVM. Meniscal extrusion and degeneration during the course of osteoarthritis in the Murine collagenase-induced osteoarthritis model. J Orthop Res 2018; 36:2416-2420. [PMID: 29624738 PMCID: PMC6175183 DOI: 10.1002/jor.23909] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/29/2018] [Accepted: 03/30/2018] [Indexed: 02/04/2023]
Abstract
Meniscal damage is, despite its major role in knee osteoarthritis (OA), often neglected in OA animal models. We evaluated structural meniscal degeneration during the course of OA in the murine collagenase-induced OA (CIOA) model. To investigate this, OA was induced in the knee joints of 33 male C57BL/6 mice by an intra-articular injection of 10U collagenase. The mice were sacrificed after 1, 3, 7, 14, 28, and 56 days, and the knees were harvested and processed for histological analysis. As control, six knees were obtained from 16-week-old mice in which no OA was induced. Meniscal damage, meniscal extrusion, and articular cartilage damage were evaluated on thionin-stained sections. Associations between parameters of interest were evaluated with Spearman rho correlation tests. When compared to non-OA knees, meniscal extrusion was visible from day 1 onwards and meniscal degeneration had a tendency to increase over time. The meniscus damage appeared around the same time as articular cartilage damage (day 14-28) and was statistically significantly more pronounced anterior than posterior, and no differences were seen between medial and lateral menisci. Meniscus and articular cartilage damage were moderately associated in the CIOA knees (ρ = 0.57; 95%CI [0.23-0.78]). Our findings suggest that the CIOA model is a valuable model to study the role of meniscal damage during OA progression and can support the development of future preventative treatment strategies. © 2018 The Authors. Journal of Orthopaedic Research® Published by Wiley Periodicals, Inc. on behalf of the Orthopaedic Research Society. J Orthop Res 36:2416-2420, 2018.
Collapse
Affiliation(s)
- Lizette Utomo
- Department of Orthopaedic Surgery, Erasmus MCUniversity Medical Center RotterdamRotterdamThe Netherlands
| | - Susanne M. Eijgenraam
- Department of Orthopaedic Surgery, Erasmus MCUniversity Medical Center RotterdamRotterdamThe Netherlands,Department of Radiology and Nuclear Medicine, Erasmus MCUniversity Medical Center RotterdamRotterdamThe Netherlands
| | - Duncan E. Meuffels
- Department of Orthopaedic Surgery, Erasmus MCUniversity Medical Center RotterdamRotterdamThe Netherlands
| | - Sita M. A. Bierma‐Zeinstra
- Department of Orthopaedic Surgery, Erasmus MCUniversity Medical Center RotterdamRotterdamThe Netherlands,Department of General Practice, Erasmus MCUniversity Medical Center RotterdamRotterdamThe Netherlands
| | | | - Gerjo J. V. M. van Osch
- Department of Orthopaedic Surgery, Erasmus MCUniversity Medical Center RotterdamRotterdamThe Netherlands,Department of Otorhinolaryngology, Erasmus MCUniversity Medical Center RotterdamWytemaweg 80, Room Ee 16.55, 3015 CNRotterdamThe Netherlands
| |
Collapse
|
28
|
Fahmy-Garcia S, van Driel M, Witte-Buoma J, Walles H, van Leeuwen JPTM, van Osch GJVM, Farrell E. NELL-1, HMGB1, and CCN2 Enhance Migration and Vasculogenesis, But Not Osteogenic Differentiation Compared to BMP2. Tissue Eng Part A 2017; 24:207-218. [PMID: 28463604 DOI: 10.1089/ten.tea.2016.0537] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Currently, autografts still represent the gold standard treatment for the repair of large bone defects. However, these are associated with donor-site morbidity and increased pain, cost, and recovery time. The ideal therapy would use biomaterials combined with bone growth factors to induce and instruct bone defect repair without the need to harvest patient tissue. In this line, bone morphogenetic proteins (BMPs) have been the most extensively used agents for clinical bone repair, but at supraphysiological doses that are not without risk. Because of the need to eliminate the risks of BMP2 use in vivo, we assessed the ability of three putative osteogenic factors, nel-like molecule type 1 (NELL-1), high mobility group box 1 (HMGB1), and CCN2, to enhance the essential processes for bone defect repair in vitro and compared them to BMP2. Although it has been reported that NELL-1, HMGB1, and CCN2 play a role in bone formation, less is known about the contribution of these proteins to the different events involved, such as cell migration, osteogenesis, and vasculogenesis. In this study, we investigated the effects of different doses of NELL-1, HMGB, CCN2, and BMP2 on these three processes as a model for the recruitment and differentiation of resident cells in the in vivo bone defect repair situation, using cells of human origin. Our data demonstrated that NELL-1, HMGB1, and CCN2 significantly induced mesenchymal stem cell migration (from 1.58-fold increase compared to control), but BMP2 did not. Interestingly, only BMP2 increased osteogenesis in marrow stromal cells, whereas it inhibited osteogenesis in preosteoblasts. Moreover, the four proteins studied promoted significantly endothelial cell migration, reaching a maximum of 2.4-fold increase compared to control, and induced formation of tube-like structures. NELL-1, HMGB1, and CCN2 had these effects at relatively low doses compared to BMP2. This work indicates that NELL-1, HMGB1, and CCN2 might enhance bone defect healing via the recruitment of endogenous cells and induction of vascularization and act via different processes than BMP2.
Collapse
Affiliation(s)
| | | | - Janneke Witte-Buoma
- 3 Department of Oral and Maxillofacial Surgery, Erasmus MC , Rotterdam, The Netherlands
| | - Heike Walles
- 4 Department Tissue Engineering and Regenerative Medicine, University Hospital Würzburg , Würzburg, Germany
| | | | - Gerjo J V M van Osch
- 1 Department of Orthopaedics, Erasmus MC , Rotterdam, The Netherlands .,5 Otorhinolaryngology Department, Erasmus MC, Rotterdam, The Netherlands
| | - Eric Farrell
- 3 Department of Oral and Maxillofacial Surgery, Erasmus MC , Rotterdam, The Netherlands
| |
Collapse
|
29
|
Schneider C, Lehmann J, van Osch GJVM, Hildner F, Teuschl A, Monforte X, Miosga D, Heimel P, Priglinger E, Redl H, Wolbank S, Nürnberger S. Systematic Comparison of Protocols for the Preparation of Human Articular Cartilage for Use as Scaffold Material in Cartilage Tissue Engineering. Tissue Eng Part C Methods 2017; 22:1095-1107. [PMID: 27846786 DOI: 10.1089/ten.tec.2016.0380] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
Natural extracellular matrix-derived biomaterials from decellularized allogenic tissues are of increasing interest for tissue engineering because their structure and composition provide a complexity that is not achievable with current manufacturing techniques. The prerequisite to bring allogenic tissue from bench to bedside as a functional biomaterial is the full removal of cells while preserving most of its native characteristics such as structure and composition. The exceptionally dense structure of articular cartilage, however, poses a special challenge for decellularization, scaffold preparation, and reseeding. Therefore, we tested 24 different protocols aiming to remove cells and glycosaminoglycans (GAG) while preserving the collagen backbone and ultrastructure. The resulting matrices were analyzed for cell removal (DNA quantification, haematoxylin and eosin staining), GAG content (dimethyl methylene blue assay, Alcian blue staining and micro-computed tomography), collagen integrity (immunohistochemistry and ultrastructure), and biomechanics (compression test). Furthermore, seeding tests were conducted to evaluate cell viability and attachment to the scaffolds. Sodium dodecyl sulfate-based protocols yielded satisfactory reduction of DNA content, yet had negative effects on cell viability and attachment. Hydrochloric acid efficiently decellularized the scaffold and pepsin emerged as best option for GAG depletion. Combining these two reagents led to our final protocol, most efficient in DNA and GAG depletion while preserving the collagen architecture. The compressive modulus decreased in the absence of GAG to ∼1/3 of native cartilage, which is significantly higher than that by commercially available scaffolds tested as a reference (ranging from 1/25 to 1/100 of native cartilage). Cytocompatibility tests showed that human adipose-derived stromal cells readily adhered to the scaffold. In this study, we established a protocol combining freeze-thaw cycles, osmotic shock, and treatment with hydrochloric acid followed by a pepsin digestion step, achieving successful decellularization and GAG depletion within 1 week, resulting in a cytocompatible material with intact collagen structure. The protocol provides a basis for the generation of allogeneic scaffolds, potentially substituting manufactured scaffolds currently used in clinical articular cartilage treatment.
Collapse
Affiliation(s)
- Cornelia Schneider
- 1 Ludwig Boltzmann Institute for Experimental and Clinical Traumatology , Vienna, Austria .,2 Austrian Cluster for Tissue Regeneration, Vienna, Austria
| | - Johannes Lehmann
- 3 Department of Otorhinolaryngology and Cell Biology, Erasmus MC, University Medical Center , Rotterdam, The Netherlands
| | - Gerjo J V M van Osch
- 4 Department of Otorhinolaryngology and Orthopaedics, Erasmus MC, University Medical Center , Rotterdam, The Netherlands
| | - Florian Hildner
- 2 Austrian Cluster for Tissue Regeneration, Vienna, Austria .,5 Red Cross Blood Transfusion Center of Upper Austria , Linz, Austria
| | - Andreas Teuschl
- 2 Austrian Cluster for Tissue Regeneration, Vienna, Austria .,6 Department of Biochemical Engineering, University of Applied Sciences Technikum Wien , Vienna, Austria
| | - Xavier Monforte
- 6 Department of Biochemical Engineering, University of Applied Sciences Technikum Wien , Vienna, Austria
| | - David Miosga
- 7 Department of Trauma Surgery, Medical University, Vienna, Austria
| | - Patrick Heimel
- 1 Ludwig Boltzmann Institute for Experimental and Clinical Traumatology , Vienna, Austria .,2 Austrian Cluster for Tissue Regeneration, Vienna, Austria .,8 Karl Donath Laboratory for Hard Tissue and Biomaterial Research, School of Dentistry Medical University of Vienna , Austria
| | - Eleni Priglinger
- 1 Ludwig Boltzmann Institute for Experimental and Clinical Traumatology , Vienna, Austria .,2 Austrian Cluster for Tissue Regeneration, Vienna, Austria
| | - Heinz Redl
- 1 Ludwig Boltzmann Institute for Experimental and Clinical Traumatology , Vienna, Austria .,2 Austrian Cluster for Tissue Regeneration, Vienna, Austria
| | - Suanne Wolbank
- 1 Ludwig Boltzmann Institute for Experimental and Clinical Traumatology , Vienna, Austria .,2 Austrian Cluster for Tissue Regeneration, Vienna, Austria
| | - Sylvia Nürnberger
- 1 Ludwig Boltzmann Institute for Experimental and Clinical Traumatology , Vienna, Austria .,2 Austrian Cluster for Tissue Regeneration, Vienna, Austria .,7 Department of Trauma Surgery, Medical University, Vienna, Austria .,9 Bernhard Gottlieb University Clinic of Dentistry , Vienna, Austria .,10 School of Dentistry Medical University of Vienna , Competence Center for Morphology, Vienna, Austria
| |
Collapse
|
30
|
de Kroon LMG, Davidson ENB, Narcisi R, Farrell E, van der Kraan PM, van Osch GJVM. Activin and Nodal Are Not Suitable Alternatives to TGFβ for Chondrogenic Differentiation of Mesenchymal Stem Cells. Cartilage 2017; 8:432-438. [PMID: 28934877 PMCID: PMC5613891 DOI: 10.1177/1947603516667585] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Objective Previously, we demonstrated the importance of transforming growth factor-β (TGFβ)-activated SMAD2/3 signaling in chondrogenesis of bone marrow-derived mesenchymal stem cells (BMSCs). However, TGFβ also signals via the SMAD1/5/9 pathway, which is known to induce terminal differentiation of BMSCs. In this study, we investigated whether other SMAD2/3-activating ligands, Activin and Nodal, can induce chondrogenic differentiation of BMSCs without inducing terminal differentiation. Design Activation of SMAD2/3 signaling and chondrogenesis were evaluated in human BMSCs ( N = 3 donors) stimulated with TGFβ, Activin, or Nodal. SMAD2/3 activation was assessed by determining phosphorylated-SMAD2 (pSMAD2) protein levels and SMAD2/3-target gene expression of SERPINE1. Chondrogenesis was determined by ACAN and COL2A1 transcript analysis and histological examination of proteoglycans and collagen type II. Results Both Activin and TGFβ enhanced pSMAD2 and SERPINE1 expression compared to the control condition without growth factors, demonstrating activated SMAD2/3 signaling. pSMAD2 and SERPINE1 had a higher level of expression following stimulation with TGFβ than with Activin, while Nodal did not activate SMAD2/3 signaling. Of the 3 ligands tested, only TGFβ induced chondrogenic differentiation as shown by strongly increased transcript levels of ACAN and COL2A1 and positive histological staining of proteoglycans and collagen type II. Conclusions Even with concentrations up to 25 times higher than that of TGFβ, Activin and Nodal do not induce chondrogenic differentiation of BMSCs; thus, neither of the 2 ligands is an interesting alternative candidate for TGFβ to induce chondrogenesis without terminal differentiation. To obtain stable cartilage formation by BMSCs, future studies should decipher how TGFβ-induced terminal differentiation can be prevented.
Collapse
Affiliation(s)
- Laurie M. G. de Kroon
- Department of Rheumatology, Experimental Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands,Department of Orthopaedics, Erasmus MC University Medical Center, Rotterdam, Netherlands
| | | | - Roberto Narcisi
- Department of Orthopaedics, Erasmus MC University Medical Center, Rotterdam, Netherlands
| | - Eric Farrell
- Department of Oral and Maxillofacial Surgery, Special Dental Care and Orthodontics, Erasmus MC University Medical Center, Rotterdam, Netherlands
| | - Peter M. van der Kraan
- Department of Rheumatology, Experimental Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands
| | - Gerjo J. V. M. van Osch
- Department of Orthopaedics, Erasmus MC University Medical Center, Rotterdam, Netherlands,Department of Otorhinolaryngology, Erasmus MC University Medical Center, Rotterdam, Netherlands,Gerjo J. V. M. van Osch, Erasmus MC University Medical Center, Departments of Orthopaedics and Otorhinolaryngology, Room Ee1655, Wytemaweg 80, 3015 CN Rotterdam, Netherlands.
| |
Collapse
|
31
|
de Jong AJ, Klein-Wieringa IR, Andersen SN, Kwekkeboom JC, Herb-van Toorn L, de Lange-Brokaar BJE, van Delft D, Garcia J, Wei W, van der Heide HJL, Bastiaansen-Jenniskens YM, van Osch GJVM, Zuurmond AM, Stojanovic-Susulic V, Nelissen RGHH, Toes REM, Kloppenburg M, Ioan-Facsinay A. Lack of high BMI-related features in adipocytes and inflammatory cells in the infrapatellar fat pad (IFP). Arthritis Res Ther 2017; 19:186. [PMID: 28800775 PMCID: PMC5553811 DOI: 10.1186/s13075-017-1395-9] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2017] [Accepted: 07/24/2017] [Indexed: 01/02/2023] Open
Abstract
Background Obesity is associated with the development and progression of osteoarthritis (OA). Although the infrapatellar fat pad (IFP) could be involved in this association, due to its intracapsular localization in the knee joint, there is currently little known about the effect of obesity on the IFP. Therefore, we investigated cellular and molecular body mass index (BMI)-related features in the IFP of OA patients. Methods Patients with knee OA (N = 155, 68% women, mean age 65 years, mean (SD) BMI 29.9 kg/m2 (5.7)) were recruited: IFP volume was determined by magnetic resonance imaging in 79 patients with knee OA, while IFPs and subcutaneous adipose tissue (SCAT) were obtained from 106 patients undergoing arthroplasty. Crown-like structures (CLS) were determined using immunohistochemical analysis. Adipocyte size was determined by light microscopy and histological analysis. Stromal vascular fraction (SVF) cells were characterized by flow cytometry. Results IFP volume (mean (SD) 23.6 (5.4) mm3) was associated with height, but not with BMI or other obesity-related features. Likewise, volume and size of IFP adipocytes (mean 271 pl, mean 1933 μm) was not correlated with BMI. Few CLS were observed in the IFP, with no differences between overweight/obese and lean individuals. Moreover, high BMI was not associated with higher SVF immune cell numbers in the IFP, nor with changes in their phenotype. No BMI-associated molecular differences were observed, besides an increase in TNFα expression with high BMI. Macrophages in the IFP were mostly pro-inflammatory, producing IL-6 and TNFα, but little IL-10. Interestingly, however, CD206 and CD163 were associated with an anti-inflammatory phenotype, were the most abundantly expressed surface markers on macrophages (81% and 41%, respectively) and CD163+ macrophages had a more activated and pro-inflammatory phenotype than their CD163- counterparts. Conclusions BMI-related features usually observed in SCAT and visceral adipose tissue could not be detected in the IFP of OA patients, a fat depot implicated in OA pathogenesis. Electronic supplementary material The online version of this article (doi:10.1186/s13075-017-1395-9) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Anja J de Jong
- Department of Rheumatology, Leiden University Medical Centre, C1-R, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
| | - Inge R Klein-Wieringa
- Department of Rheumatology, Leiden University Medical Centre, C1-R, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
| | - Stefan N Andersen
- Department of Rheumatology, Leiden University Medical Centre, C1-R, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
| | - Joanneke C Kwekkeboom
- Department of Rheumatology, Leiden University Medical Centre, C1-R, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
| | - Linda Herb-van Toorn
- Department of Rheumatology, Leiden University Medical Centre, C1-R, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
| | - Badelog J E de Lange-Brokaar
- Department of Rheumatology, Leiden University Medical Centre, C1-R, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
| | - Danny van Delft
- Department of Orthopaedics, Leiden University Medical Center, Leiden, The Netherlands
| | - John Garcia
- Department of Orthopaedics, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.,ISTM, Keele University, Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, Shropshire, UK
| | - Wu Wei
- Department of Orthopaedics, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | | | | | - Gerjo J V M van Osch
- Department of Orthopaedics, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | | | | | - Rob G H H Nelissen
- Department of Orthopaedics, Leiden University Medical Center, Leiden, The Netherlands
| | - René E M Toes
- Department of Rheumatology, Leiden University Medical Centre, C1-R, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
| | - Margreet Kloppenburg
- Department of Rheumatology, Leiden University Medical Centre, C1-R, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
| | - Andreea Ioan-Facsinay
- Department of Rheumatology, Leiden University Medical Centre, C1-R, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
| |
Collapse
|
32
|
Wei W, Bastiaansen-Jenniskens YM, Suijkerbuijk M, Kops N, Bos PK, Verhaar JAN, Zuurmond AM, Dell'Accio F, van Osch GJVM. High fat diet accelerates cartilage repair in DBA/1 mice. J Orthop Res 2017; 35:1258-1264. [PMID: 27147295 DOI: 10.1002/jor.23280] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/09/2015] [Accepted: 04/30/2016] [Indexed: 02/04/2023]
Abstract
Obesity is a well-known risk factor for osteoarthritis, but it is unknown what it does on cartilage repair. Here we investigated whether a high fat diet (HFD) influences cartilage repair in a mouse model of cartilage repair. We fed DBA/1 mice control or HFD (60% energy from fat). After 2 weeks, a full thickness cartilage defect was made in the trochlear groove. Mice were sacrificed, 1, 8, and 24 weeks after operation. Cartilage repair was evaluated on histology. Serum glucose, insulin and amyloid A were measured 24 h before operation and at endpoints. Immunohistochemical staining was performed on synovium and adipose tissue to evaluate macrophage infiltration and phenotype. One week after operation, mice on HFD had defect filling with fibroblast-like cells and more cartilage repair as indicated by a lower Pineda score. After 8 weeks, mice on a HFD still had a lower Pineda score. After 24 weeks, no mice had complete cartilage repair and we did not detect a significant difference in cartilage repair between diets. Bodyweight was increased by HFD, whereas serum glucose, amyloid A and insulin were not influenced. Macrophage infiltration and phenotype in adipose tissue and synovium were not influenced by HFD. In contrast to common wisdom, HFD accelerated intrinsic cartilage repair in DBA/1 mice on the short term. Resistance to HFD induced inflammatory and metabolic changes could be associated with accelerated cartilage repair. © 2017 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 35:1258-1264, 2017.
Collapse
Affiliation(s)
- Wu Wei
- Department of Orthopaedics, Erasmus MC University Medical Center, Rotterdam, The Netherlands
| | | | - Mathijs Suijkerbuijk
- Department of Orthopaedics, Erasmus MC University Medical Center, Rotterdam, The Netherlands
| | - Nicole Kops
- Department of Orthopaedics, Erasmus MC University Medical Center, Rotterdam, The Netherlands
| | - Pieter K Bos
- Department of Orthopaedics, Erasmus MC University Medical Center, Rotterdam, The Netherlands
| | - Jan A N Verhaar
- Department of Orthopaedics, Erasmus MC University Medical Center, Rotterdam, The Netherlands
| | | | | | - Gerjo J V M van Osch
- Department of Orthopaedics, Erasmus MC University Medical Center, Rotterdam, The Netherlands
- Department of Otorhinolaryngology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
| |
Collapse
|
33
|
Lolli A, Penolazzi L, Narcisi R, van Osch GJVM, Piva R. Emerging potential of gene silencing approaches targeting anti-chondrogenic factors for cell-based cartilage repair. Cell Mol Life Sci 2017; 74:3451-3465. [PMID: 28434038 DOI: 10.1007/s00018-017-2531-z] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2017] [Revised: 04/14/2017] [Accepted: 04/19/2017] [Indexed: 12/18/2022]
Abstract
The field of cartilage repair has exponentially been growing over the past decade. Here, we discuss the possibility to achieve satisfactory regeneration of articular cartilage by means of human mesenchymal stem cells (hMSCs) depleted of anti-chondrogenic factors and implanted in the site of injury. Different types of molecules including transcription factors, transcriptional co-regulators, secreted proteins, and microRNAs have recently been identified as negative modulators of chondroprogenitor differentiation and chondrocyte function. We review the current knowledge about these molecules as potential targets for gene knockdown strategies using RNA interference (RNAi) tools that allow the specific suppression of gene function. The critical issues regarding the optimization of the gene silencing approach as well as the delivery strategies are discussed. We anticipate that further development of these techniques will lead to the generation of implantable hMSCs with enhanced potential to regenerate articular cartilage damaged by injury, disease, or aging.
Collapse
Affiliation(s)
- Andrea Lolli
- Department of Orthopaedics, Erasmus MC, University Medical Center, 3015 CN, Rotterdam, The Netherlands.
| | - Letizia Penolazzi
- Department of Biomedical and Specialty Surgical Sciences, University of Ferrara, Ferrara, Italy
| | - Roberto Narcisi
- Department of Orthopaedics, Erasmus MC, University Medical Center, 3015 CN, Rotterdam, The Netherlands
| | - Gerjo J V M van Osch
- Department of Orthopaedics, Erasmus MC, University Medical Center, 3015 CN, Rotterdam, The Netherlands.,Department of Otorhinolaryngology, Erasmus MC, University Medical Center, 3015 CN, Rotterdam, The Netherlands
| | - Roberta Piva
- Department of Biomedical and Specialty Surgical Sciences, University of Ferrara, Ferrara, Italy.
| |
Collapse
|
34
|
Leijs MJC, van Buul GM, Verhaar JAN, Hoogduijn MJ, Bos PK, van Osch GJVM. Pre-Treatment of Human Mesenchymal Stem Cells With Inflammatory Factors or Hypoxia Does Not Influence Migration to Osteoarthritic Cartilage and Synovium. Am J Sports Med 2017; 45:1151-1161. [PMID: 28114800 DOI: 10.1177/0363546516682710] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
BACKGROUND Mesenchymal stem cells (MSCs) are promising candidates as a cell-based therapy for osteoarthritis (OA), although current results are modest. Pre-treatment of MSCs before application might improve their therapeutic efficacy. HYPOTHESIS Pre-treatment of MSCs with inflammatory factors or hypoxia will improve their migration and adhesion capacities toward OA-affected tissues. STUDY DESIGN Controlled laboratory study. METHODS We used real-time polymerase chain reaction to determine the effects of different fetal calf serum (FCS) batches, platelet lysate (PL), hypoxia, inflammatory factors, factors secreted by OA tissues, and OA synovial fluid (SF) on the expression of 12 genes encoding chemokine or adhesion receptors. Migration of MSCs toward factors secreted by OA tissues was studied in vitro, and attachment of injected MSCs was evaluated in vivo in healthy and OA knees of male Wistar rats. RESULTS Different FCS batches, PL, or hypoxia did not influence the expression of the migration and adhesion receptor genes. Exposure to inflammatory factors altered the expression of CCR1, CCR4, CD44, PDGFRα, and PDGFRβ. MSCs migrated toward factors secreted by OA tissues in vitro. Neither pre-treatment with inflammatory factors nor the presence of OA influenced MSC migration in vitro or adhesion in vivo. CONCLUSION Factors secreted by OA tissues increase MSC migration in vitro. In vivo, no difference in MSC adhesion was found between OA and healthy knees. Pre-treatment with inflammatory factors influenced the expression of migration and adhesion receptors of MSCs but not their migration in vitro or adhesion in vivo. CLINICAL RELEVANCE To improve the therapeutic capacity of intra-articular injection of MSCs, they need to remain intra-articular for a longer period of time. Pre-treatment of MSCs with hypoxia or inflammatory factors did not increase the migration or adhesion capacity of MSCs and will therefore not likely prolong their intra-articular longevity. Alternative approaches to prolong the intra-articular presence of MSCs should be developed to increase the therapeutic effect of MSCs in OA.
Collapse
Affiliation(s)
- Maarten J C Leijs
- Department of Orthopaedics, Erasmus MC Rotterdam, the Netherlands.,Department of Radiology, Erasmus MC Rotterdam, the Netherlands
| | | | - Jan A N Verhaar
- Department of Orthopaedics, Erasmus MC Rotterdam, the Netherlands
| | | | - Pieter K Bos
- Department of Orthopaedics, Erasmus MC Rotterdam, the Netherlands
| | - Gerjo J V M van Osch
- Department of Orthopaedics, Erasmus MC Rotterdam, the Netherlands.,Department of Otorhinolaryngology, Erasmus MC Rotterdam, the Netherlands
| |
Collapse
|
35
|
Cleary MA, Narcisi R, Albiero A, Jenner F, de Kroon LMG, Koevoet WJLM, Brama PAJ, van Osch GJVM. Dynamic Regulation of TWIST1 Expression During Chondrogenic Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells. Stem Cells Dev 2017; 26:751-761. [PMID: 28300491 DOI: 10.1089/scd.2016.0308] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Human bone marrow-derived mesenchymal stem cells (BMSCs) are clinically promising to repair damaged articular cartilage. This study investigated TWIST1, an important transcriptional regulator in mesenchymal lineages, in BMSC chondrogenesis. We hypothesized that downregulation of TWIST1 expression is required for in vitro chondrogenic differentiation. Indeed, significant downregulation of TWIST1 was observed in murine skeletal progenitor cells during limb development (N = 3 embryos), and during chondrogenic differentiation of culture-expanded human articular chondrocytes (N = 3 donors) and isolated adult human BMSCs (N = 7 donors), consistent with an inhibitory effect of TWIST1 expression on chondrogenic differentiation. Silencing of TWIST1 expression in BMSCs by siRNA, however, did not improve chondrogenic differentiation potential. Interestingly, additional investigation revealed that downregulation of TWIST1 in chondrogenic BMSCs is preceded by an initial upregulation. Similar upregulation is observed in non-chondrogenic BMSCs (N = 5 donors); however, non-chondrogenic cells fail to downregulate TWIST1 expression thereafter, preventing their chondrogenic differentiation. This study describes for the first time endogenous TWIST1 expression during in vitro chondrogenic differentiation of human BMSCs, demonstrating dynamic regulation of TWIST1 expression whereby upregulation and then downregulation of TWIST1 expression are required for chondrogenic differentiation of BMSCs. Elucidation of the molecular regulation of, and by, TWIST1 will provide targets for optimization of BMSC chondrogenic differentiation culture.
Collapse
Affiliation(s)
- Mairéad A Cleary
- 1 School of Veterinary Medicine, Veterinary Clinical Sciences, University College Dublin , Dublin, Ireland .,2 Department of Orthopaedics, Erasmus MC, University Medical Center , Rotterdam, the Netherlands
| | - Roberto Narcisi
- 2 Department of Orthopaedics, Erasmus MC, University Medical Center , Rotterdam, the Netherlands
| | - Anna Albiero
- 2 Department of Orthopaedics, Erasmus MC, University Medical Center , Rotterdam, the Netherlands
| | - Florien Jenner
- 3 University of Veterinary Medicine Vienna , Equine Hospital, Vienna, Austria
| | - Laurie M G de Kroon
- 2 Department of Orthopaedics, Erasmus MC, University Medical Center , Rotterdam, the Netherlands .,4 Department of Rheumatology, Radboud University Medical Center , Nijmegen, the Netherlands
| | - Wendy J L M Koevoet
- 5 Department of Otorhinolaryngology, Erasmus MC, University Medical Center , Rotterdam, the Netherlands
| | - Pieter A J Brama
- 1 School of Veterinary Medicine, Veterinary Clinical Sciences, University College Dublin , Dublin, Ireland
| | - Gerjo J V M van Osch
- 2 Department of Orthopaedics, Erasmus MC, University Medical Center , Rotterdam, the Netherlands .,5 Department of Otorhinolaryngology, Erasmus MC, University Medical Center , Rotterdam, the Netherlands
| |
Collapse
|
36
|
Saltzherr MS, Coert JH, Selles RW, van Neck JW, Jaquet JB, van Osch GJVM, Oei EHG, Luime JJ, Muradin GSR. Accuracy of magnetic resonance imaging to detect cartilage loss in severe osteoarthritis of the first carpometacarpal joint: comparison with histological evaluation. Arthritis Res Ther 2017; 19:55. [PMID: 28288684 PMCID: PMC5348904 DOI: 10.1186/s13075-017-1262-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2016] [Accepted: 02/14/2017] [Indexed: 11/21/2022] Open
Abstract
Background Magnetic resonance imaging (MRI) is increasingly used for research in hand osteoarthritis, but imaging the thin cartilage layers in the hand joints remains challenging. We therefore assessed the accuracy of MRI in detecting cartilage loss in patients with symptomatic osteoarthritis of the first carpometacarpal (CMC1) joint. Methods Twelve patients scheduled for trapeziectomy to treat severe symptomatic osteoarthritis of the CMC1 joint underwent a preoperative high resolution 3D spoiled gradient (SPGR) MRI scan. Subsequently, the resected trapezium was evaluated histologically. The sections were scored for cartilage damage severity (Osteoarthritis Research Society International (OARSI) score), and extent of damage (percentage surface area). Each MRI scan was scored for the area of normal cartilage, partial cartilage loss and full cartilage loss. The percentages of the total surface area with any cartilage loss and full-thickness cartilage loss were calculated using MRI and histological evaluation. Results MRI and histological evaluation both identified large areas of overall cartilage loss. The median (IQR) surface area of any cartilage loss on MRI was 98% (82–100%), and on histological assessment 96% (87–98%). However, MRI underestimated the extent of full-thickness cartilage loss. The median (IQR) surface area of full-thickness cartilage loss on MRI was 43% (22–70%), and on histological evaluation 79% (67–85%). The difference was caused by a thin layer of high signal on the articulating surface, which was interpreted as damaged cartilage on MRI but which was not identified on histological evaluation. Conclusions Three-dimensional SPGR MRI of the CMC1 joint demonstrates overall cartilage damage, but underestimates full-thickness cartilage loss in patients with advanced osteoarthritis.
Collapse
Affiliation(s)
- Michael S Saltzherr
- Department of Radiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. .,Department of Plastic, Reconstructive and Hand Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. .,Department of Rheumatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
| | - J Henk Coert
- Department of Plastic, Reconstructive and Hand Surgery, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Ruud W Selles
- Department of Plastic, Reconstructive and Hand Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.,Department of Rehabilitation Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Johan W van Neck
- Department of Plastic, Reconstructive and Hand Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Jean-Bart Jaquet
- Department of Plastic, Reconstructive and Hand surgery, Maasstad Hospital, Rotterdam, The Netherlands
| | - Gerjo J V M van Osch
- Department of Orthopaedics and Department of Otorhinolaryngology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Edwin H G Oei
- Department of Radiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Jolanda J Luime
- Department of Rheumatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Galied S R Muradin
- Department of Radiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| |
Collapse
|
37
|
Utomo L, Boersema GSA, Bayon Y, Lange JF, van Osch GJVM, Bastiaansen-Jenniskens YM. In vitro modulation of the behavior of adhering macrophages by medications is biomaterial-dependent. ACTA ACUST UNITED AC 2017; 12:025006. [PMID: 28267684 DOI: 10.1088/1748-605x/aa5cbc] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
After implantation of a biomaterial, an inflammatory response involving macrophages is induced. The behavior of macrophages depends on their phenotype, and by directing macrophage polarization unwanted effects may be avoided. In this study, the possibility to modulate the behavior of macrophages activated by biomaterials was assessed in an in vitro model. Primary human monocytes were seeded on polyethylene terephthalate, polypropylene and polylactic acid yarns, and treated with medications frequently used by patients: rapamycin, dexamethasone, celecoxib or pravastatin. Modulation of the adhering macrophages with rapamycin resulted in a generally pro-inflammatory effect. Dexamethasone caused an overall anti-inflammatory effect on the macrophages cultured on either material, while celecoxib only affected macrophages adhering to polyethylene terephthalate and polylactic acid. Pravastatin increased the pro-inflammatory genes of macrophages cultured on polypropylene and polylactic acid. Pairwise comparison revealed that macrophages adhering to polylactic acid seemed to be more susceptible to phenotype modulation than when adhering to polypropylene or polyethylene terephthalate. The data show that macrophages activated by the biomaterials can be modulated, yet the degree of the modulatory capacity depends on the type of material. Combined, this model provides insights into the possibility of using a medication in combination with a biomaterial to direct macrophage behavior and thereby possibly avoid unwanted effects after implantation.
Collapse
Affiliation(s)
- Lizette Utomo
- Department of Orthopaedics, Erasmus MC, University Medical Center, Rotterdam, Netherlands
| | | | | | | | | | | |
Collapse
|
38
|
Klein-Wieringa IR, de Lange-Brokaar BJE, Yusuf E, Andersen SN, Kwekkeboom JC, Kroon HM, van Osch GJVM, Zuurmond AM, Stojanovic-Susulic V, Nelissen RGHH, Toes REM, Kloppenburg M, Ioan-Facsinay A. Inflammatory Cells in Patients with Endstage Knee Osteoarthritis: A Comparison between the Synovium and the Infrapatellar Fat Pad. J Rheumatol 2016; 43:771-8. [PMID: 26980579 DOI: 10.3899/jrheum.151068] [Citation(s) in RCA: 100] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/18/2016] [Indexed: 12/13/2022]
Abstract
OBJECTIVE To get a better understanding of inflammatory pathways active in the osteoarthritic (OA) joint, we characterized and compared inflammatory cells in the synovium and the infrapatellar fat pad (IFP) of patients with knee OA. METHODS Infiltrating immune cells were characterized by flow cytometry in 76 patients with knee OA (mean age 63.3, 52% women, median body mass index 28.9) from whom synovial tissue (n = 40) and IFP (n = 68) samples were obtained. Pain was assessed by the visual analog scale (VAS; 0-100 mm). Spearman rank correlations and linear regression analyses adjusted for sex and age were performed. RESULTS Macrophages and T cells, followed by mast cells, were the most predominant immune cells in the synovium and IFP, and were equally abundant in these tissues. Macrophages and T cells secreted mostly proinflammatory cytokines even without additional stimulation, indicating their activated state. Accordingly, most CD4+ T cells had a memory phenotype and contained a significant population of cells expressing activation markers (CD25+, CD69+). Interestingly, the percent of CD69+ T cells was higher in synovial than IFP CD4+ T cells. Preliminary analyses indicated that the number of synovial CD4+ T cells were associated with VAS pain (β 0.51, 95% CI 0.09-1.02, p = 0.02). CONCLUSION Our data suggest that the immune cell composition of the synovium and the IFP is similar, and includes activated cells that could contribute to inflammation through secretion of proinflammatory cytokines. Moreover, preliminary analyses indicate that synovial CD4+ T cells might associate with pain in patients with endstage OA of the knee.
Collapse
Affiliation(s)
- Inge R Klein-Wieringa
- From the Department of Rheumatology, Leiden University Medical Centre; Department of Radiology, Department of Orthopedics, and Department of Clinical Epidemiology, Leiden University Medical Center; TNO, Leiden; Department of Orthopedics and Otorhinolaryngology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; The Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania, USA.I.R. Klein-Wieringa*, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; B.J. de Lange-Brokaar*, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; E. Yusuf, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; S.N. Andersen, Ing, Department of Rheumatology, Leiden University Medical Centre; J.C. Kwekkeboom, Ing, Department of Rheumatology, Leiden University Medical Centre; H.M. Kroon, PhD, Department of Radiology, Leiden University Medical Center; G.J. van Osch, PhD, Professor, Department of Orthopedics and Otorhinolaryngology, Erasmus MC, University Medical Center; A.M. Zuurmond, PhD, TNO; V. Stojanovic-Susulic, PhD, Janssen Pharmaceutical Companies of Johnson & Johnson; R.G. Nelissen, MD, PhD, Professor, Department of Orthopedics, Leiden University Medical Center; R.E. Toes, PhD, Professor, Department of Rheumatology, Leiden University Medical Centre; M. Kloppenburg, MD, PhD, Professor, Department of Rheumatology, and Department of Clinical Epidemiology, Leiden University Medical Centre; A. Ioan-Facsinay, PhD, Assistant Professor, Department of Rheumatology, Leiden University Medical Centre
| | - Badelog J E de Lange-Brokaar
- From the Department of Rheumatology, Leiden University Medical Centre; Department of Radiology, Department of Orthopedics, and Department of Clinical Epidemiology, Leiden University Medical Center; TNO, Leiden; Department of Orthopedics and Otorhinolaryngology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; The Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania, USA.I.R. Klein-Wieringa*, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; B.J. de Lange-Brokaar*, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; E. Yusuf, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; S.N. Andersen, Ing, Department of Rheumatology, Leiden University Medical Centre; J.C. Kwekkeboom, Ing, Department of Rheumatology, Leiden University Medical Centre; H.M. Kroon, PhD, Department of Radiology, Leiden University Medical Center; G.J. van Osch, PhD, Professor, Department of Orthopedics and Otorhinolaryngology, Erasmus MC, University Medical Center; A.M. Zuurmond, PhD, TNO; V. Stojanovic-Susulic, PhD, Janssen Pharmaceutical Companies of Johnson & Johnson; R.G. Nelissen, MD, PhD, Professor, Department of Orthopedics, Leiden University Medical Center; R.E. Toes, PhD, Professor, Department of Rheumatology, Leiden University Medical Centre; M. Kloppenburg, MD, PhD, Professor, Department of Rheumatology, and Department of Clinical Epidemiology, Leiden University Medical Centre; A. Ioan-Facsinay, PhD, Assistant Professor, Department of Rheumatology, Leiden University Medical Centre
| | - Erlangga Yusuf
- From the Department of Rheumatology, Leiden University Medical Centre; Department of Radiology, Department of Orthopedics, and Department of Clinical Epidemiology, Leiden University Medical Center; TNO, Leiden; Department of Orthopedics and Otorhinolaryngology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; The Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania, USA.I.R. Klein-Wieringa*, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; B.J. de Lange-Brokaar*, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; E. Yusuf, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; S.N. Andersen, Ing, Department of Rheumatology, Leiden University Medical Centre; J.C. Kwekkeboom, Ing, Department of Rheumatology, Leiden University Medical Centre; H.M. Kroon, PhD, Department of Radiology, Leiden University Medical Center; G.J. van Osch, PhD, Professor, Department of Orthopedics and Otorhinolaryngology, Erasmus MC, University Medical Center; A.M. Zuurmond, PhD, TNO; V. Stojanovic-Susulic, PhD, Janssen Pharmaceutical Companies of Johnson & Johnson; R.G. Nelissen, MD, PhD, Professor, Department of Orthopedics, Leiden University Medical Center; R.E. Toes, PhD, Professor, Department of Rheumatology, Leiden University Medical Centre; M. Kloppenburg, MD, PhD, Professor, Department of Rheumatology, and Department of Clinical Epidemiology, Leiden University Medical Centre; A. Ioan-Facsinay, PhD, Assistant Professor, Department of Rheumatology, Leiden University Medical Centre
| | - Stefan N Andersen
- From the Department of Rheumatology, Leiden University Medical Centre; Department of Radiology, Department of Orthopedics, and Department of Clinical Epidemiology, Leiden University Medical Center; TNO, Leiden; Department of Orthopedics and Otorhinolaryngology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; The Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania, USA.I.R. Klein-Wieringa*, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; B.J. de Lange-Brokaar*, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; E. Yusuf, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; S.N. Andersen, Ing, Department of Rheumatology, Leiden University Medical Centre; J.C. Kwekkeboom, Ing, Department of Rheumatology, Leiden University Medical Centre; H.M. Kroon, PhD, Department of Radiology, Leiden University Medical Center; G.J. van Osch, PhD, Professor, Department of Orthopedics and Otorhinolaryngology, Erasmus MC, University Medical Center; A.M. Zuurmond, PhD, TNO; V. Stojanovic-Susulic, PhD, Janssen Pharmaceutical Companies of Johnson & Johnson; R.G. Nelissen, MD, PhD, Professor, Department of Orthopedics, Leiden University Medical Center; R.E. Toes, PhD, Professor, Department of Rheumatology, Leiden University Medical Centre; M. Kloppenburg, MD, PhD, Professor, Department of Rheumatology, and Department of Clinical Epidemiology, Leiden University Medical Centre; A. Ioan-Facsinay, PhD, Assistant Professor, Department of Rheumatology, Leiden University Medical Centre
| | - Joanneke C Kwekkeboom
- From the Department of Rheumatology, Leiden University Medical Centre; Department of Radiology, Department of Orthopedics, and Department of Clinical Epidemiology, Leiden University Medical Center; TNO, Leiden; Department of Orthopedics and Otorhinolaryngology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; The Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania, USA.I.R. Klein-Wieringa*, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; B.J. de Lange-Brokaar*, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; E. Yusuf, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; S.N. Andersen, Ing, Department of Rheumatology, Leiden University Medical Centre; J.C. Kwekkeboom, Ing, Department of Rheumatology, Leiden University Medical Centre; H.M. Kroon, PhD, Department of Radiology, Leiden University Medical Center; G.J. van Osch, PhD, Professor, Department of Orthopedics and Otorhinolaryngology, Erasmus MC, University Medical Center; A.M. Zuurmond, PhD, TNO; V. Stojanovic-Susulic, PhD, Janssen Pharmaceutical Companies of Johnson & Johnson; R.G. Nelissen, MD, PhD, Professor, Department of Orthopedics, Leiden University Medical Center; R.E. Toes, PhD, Professor, Department of Rheumatology, Leiden University Medical Centre; M. Kloppenburg, MD, PhD, Professor, Department of Rheumatology, and Department of Clinical Epidemiology, Leiden University Medical Centre; A. Ioan-Facsinay, PhD, Assistant Professor, Department of Rheumatology, Leiden University Medical Centre
| | - Herman M Kroon
- From the Department of Rheumatology, Leiden University Medical Centre; Department of Radiology, Department of Orthopedics, and Department of Clinical Epidemiology, Leiden University Medical Center; TNO, Leiden; Department of Orthopedics and Otorhinolaryngology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; The Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania, USA.I.R. Klein-Wieringa*, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; B.J. de Lange-Brokaar*, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; E. Yusuf, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; S.N. Andersen, Ing, Department of Rheumatology, Leiden University Medical Centre; J.C. Kwekkeboom, Ing, Department of Rheumatology, Leiden University Medical Centre; H.M. Kroon, PhD, Department of Radiology, Leiden University Medical Center; G.J. van Osch, PhD, Professor, Department of Orthopedics and Otorhinolaryngology, Erasmus MC, University Medical Center; A.M. Zuurmond, PhD, TNO; V. Stojanovic-Susulic, PhD, Janssen Pharmaceutical Companies of Johnson & Johnson; R.G. Nelissen, MD, PhD, Professor, Department of Orthopedics, Leiden University Medical Center; R.E. Toes, PhD, Professor, Department of Rheumatology, Leiden University Medical Centre; M. Kloppenburg, MD, PhD, Professor, Department of Rheumatology, and Department of Clinical Epidemiology, Leiden University Medical Centre; A. Ioan-Facsinay, PhD, Assistant Professor, Department of Rheumatology, Leiden University Medical Centre
| | - Gerjo J V M van Osch
- From the Department of Rheumatology, Leiden University Medical Centre; Department of Radiology, Department of Orthopedics, and Department of Clinical Epidemiology, Leiden University Medical Center; TNO, Leiden; Department of Orthopedics and Otorhinolaryngology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; The Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania, USA.I.R. Klein-Wieringa*, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; B.J. de Lange-Brokaar*, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; E. Yusuf, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; S.N. Andersen, Ing, Department of Rheumatology, Leiden University Medical Centre; J.C. Kwekkeboom, Ing, Department of Rheumatology, Leiden University Medical Centre; H.M. Kroon, PhD, Department of Radiology, Leiden University Medical Center; G.J. van Osch, PhD, Professor, Department of Orthopedics and Otorhinolaryngology, Erasmus MC, University Medical Center; A.M. Zuurmond, PhD, TNO; V. Stojanovic-Susulic, PhD, Janssen Pharmaceutical Companies of Johnson & Johnson; R.G. Nelissen, MD, PhD, Professor, Department of Orthopedics, Leiden University Medical Center; R.E. Toes, PhD, Professor, Department of Rheumatology, Leiden University Medical Centre; M. Kloppenburg, MD, PhD, Professor, Department of Rheumatology, and Department of Clinical Epidemiology, Leiden University Medical Centre; A. Ioan-Facsinay, PhD, Assistant Professor, Department of Rheumatology, Leiden University Medical Centre
| | - Anne-Marie Zuurmond
- From the Department of Rheumatology, Leiden University Medical Centre; Department of Radiology, Department of Orthopedics, and Department of Clinical Epidemiology, Leiden University Medical Center; TNO, Leiden; Department of Orthopedics and Otorhinolaryngology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; The Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania, USA.I.R. Klein-Wieringa*, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; B.J. de Lange-Brokaar*, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; E. Yusuf, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; S.N. Andersen, Ing, Department of Rheumatology, Leiden University Medical Centre; J.C. Kwekkeboom, Ing, Department of Rheumatology, Leiden University Medical Centre; H.M. Kroon, PhD, Department of Radiology, Leiden University Medical Center; G.J. van Osch, PhD, Professor, Department of Orthopedics and Otorhinolaryngology, Erasmus MC, University Medical Center; A.M. Zuurmond, PhD, TNO; V. Stojanovic-Susulic, PhD, Janssen Pharmaceutical Companies of Johnson & Johnson; R.G. Nelissen, MD, PhD, Professor, Department of Orthopedics, Leiden University Medical Center; R.E. Toes, PhD, Professor, Department of Rheumatology, Leiden University Medical Centre; M. Kloppenburg, MD, PhD, Professor, Department of Rheumatology, and Department of Clinical Epidemiology, Leiden University Medical Centre; A. Ioan-Facsinay, PhD, Assistant Professor, Department of Rheumatology, Leiden University Medical Centre
| | - Vedrana Stojanovic-Susulic
- From the Department of Rheumatology, Leiden University Medical Centre; Department of Radiology, Department of Orthopedics, and Department of Clinical Epidemiology, Leiden University Medical Center; TNO, Leiden; Department of Orthopedics and Otorhinolaryngology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; The Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania, USA.I.R. Klein-Wieringa*, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; B.J. de Lange-Brokaar*, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; E. Yusuf, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; S.N. Andersen, Ing, Department of Rheumatology, Leiden University Medical Centre; J.C. Kwekkeboom, Ing, Department of Rheumatology, Leiden University Medical Centre; H.M. Kroon, PhD, Department of Radiology, Leiden University Medical Center; G.J. van Osch, PhD, Professor, Department of Orthopedics and Otorhinolaryngology, Erasmus MC, University Medical Center; A.M. Zuurmond, PhD, TNO; V. Stojanovic-Susulic, PhD, Janssen Pharmaceutical Companies of Johnson & Johnson; R.G. Nelissen, MD, PhD, Professor, Department of Orthopedics, Leiden University Medical Center; R.E. Toes, PhD, Professor, Department of Rheumatology, Leiden University Medical Centre; M. Kloppenburg, MD, PhD, Professor, Department of Rheumatology, and Department of Clinical Epidemiology, Leiden University Medical Centre; A. Ioan-Facsinay, PhD, Assistant Professor, Department of Rheumatology, Leiden University Medical Centre
| | - Rob G H H Nelissen
- From the Department of Rheumatology, Leiden University Medical Centre; Department of Radiology, Department of Orthopedics, and Department of Clinical Epidemiology, Leiden University Medical Center; TNO, Leiden; Department of Orthopedics and Otorhinolaryngology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; The Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania, USA.I.R. Klein-Wieringa*, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; B.J. de Lange-Brokaar*, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; E. Yusuf, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; S.N. Andersen, Ing, Department of Rheumatology, Leiden University Medical Centre; J.C. Kwekkeboom, Ing, Department of Rheumatology, Leiden University Medical Centre; H.M. Kroon, PhD, Department of Radiology, Leiden University Medical Center; G.J. van Osch, PhD, Professor, Department of Orthopedics and Otorhinolaryngology, Erasmus MC, University Medical Center; A.M. Zuurmond, PhD, TNO; V. Stojanovic-Susulic, PhD, Janssen Pharmaceutical Companies of Johnson & Johnson; R.G. Nelissen, MD, PhD, Professor, Department of Orthopedics, Leiden University Medical Center; R.E. Toes, PhD, Professor, Department of Rheumatology, Leiden University Medical Centre; M. Kloppenburg, MD, PhD, Professor, Department of Rheumatology, and Department of Clinical Epidemiology, Leiden University Medical Centre; A. Ioan-Facsinay, PhD, Assistant Professor, Department of Rheumatology, Leiden University Medical Centre
| | - René E M Toes
- From the Department of Rheumatology, Leiden University Medical Centre; Department of Radiology, Department of Orthopedics, and Department of Clinical Epidemiology, Leiden University Medical Center; TNO, Leiden; Department of Orthopedics and Otorhinolaryngology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; The Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania, USA.I.R. Klein-Wieringa*, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; B.J. de Lange-Brokaar*, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; E. Yusuf, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; S.N. Andersen, Ing, Department of Rheumatology, Leiden University Medical Centre; J.C. Kwekkeboom, Ing, Department of Rheumatology, Leiden University Medical Centre; H.M. Kroon, PhD, Department of Radiology, Leiden University Medical Center; G.J. van Osch, PhD, Professor, Department of Orthopedics and Otorhinolaryngology, Erasmus MC, University Medical Center; A.M. Zuurmond, PhD, TNO; V. Stojanovic-Susulic, PhD, Janssen Pharmaceutical Companies of Johnson & Johnson; R.G. Nelissen, MD, PhD, Professor, Department of Orthopedics, Leiden University Medical Center; R.E. Toes, PhD, Professor, Department of Rheumatology, Leiden University Medical Centre; M. Kloppenburg, MD, PhD, Professor, Department of Rheumatology, and Department of Clinical Epidemiology, Leiden University Medical Centre; A. Ioan-Facsinay, PhD, Assistant Professor, Department of Rheumatology, Leiden University Medical Centre
| | - Margreet Kloppenburg
- From the Department of Rheumatology, Leiden University Medical Centre; Department of Radiology, Department of Orthopedics, and Department of Clinical Epidemiology, Leiden University Medical Center; TNO, Leiden; Department of Orthopedics and Otorhinolaryngology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; The Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania, USA.I.R. Klein-Wieringa*, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; B.J. de Lange-Brokaar*, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; E. Yusuf, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; S.N. Andersen, Ing, Department of Rheumatology, Leiden University Medical Centre; J.C. Kwekkeboom, Ing, Department of Rheumatology, Leiden University Medical Centre; H.M. Kroon, PhD, Department of Radiology, Leiden University Medical Center; G.J. van Osch, PhD, Professor, Department of Orthopedics and Otorhinolaryngology, Erasmus MC, University Medical Center; A.M. Zuurmond, PhD, TNO; V. Stojanovic-Susulic, PhD, Janssen Pharmaceutical Companies of Johnson & Johnson; R.G. Nelissen, MD, PhD, Professor, Department of Orthopedics, Leiden University Medical Center; R.E. Toes, PhD, Professor, Department of Rheumatology, Leiden University Medical Centre; M. Kloppenburg, MD, PhD, Professor, Department of Rheumatology, and Department of Clinical Epidemiology, Leiden University Medical Centre; A. Ioan-Facsinay, PhD, Assistant Professor, Department of Rheumatology, Leiden University Medical Centre
| | - Andreea Ioan-Facsinay
- From the Department of Rheumatology, Leiden University Medical Centre; Department of Radiology, Department of Orthopedics, and Department of Clinical Epidemiology, Leiden University Medical Center; TNO, Leiden; Department of Orthopedics and Otorhinolaryngology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; The Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania, USA.I.R. Klein-Wieringa*, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; B.J. de Lange-Brokaar*, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; E. Yusuf, MD, PhD, Department of Rheumatology, Leiden University Medical Centre; S.N. Andersen, Ing, Department of Rheumatology, Leiden University Medical Centre; J.C. Kwekkeboom, Ing, Department of Rheumatology, Leiden University Medical Centre; H.M. Kroon, PhD, Department of Radiology, Leiden University Medical Center; G.J. van Osch, PhD, Professor, Department of Orthopedics and Otorhinolaryngology, Erasmus MC, University Medical Center; A.M. Zuurmond, PhD, TNO; V. Stojanovic-Susulic, PhD, Janssen Pharmaceutical Companies of Johnson & Johnson; R.G. Nelissen, MD, PhD, Professor, Department of Orthopedics, Leiden University Medical Center; R.E. Toes, PhD, Professor, Department of Rheumatology, Leiden University Medical Centre; M. Kloppenburg, MD, PhD, Professor, Department of Rheumatology, and Department of Clinical Epidemiology, Leiden University Medical Centre; A. Ioan-Facsinay, PhD, Assistant Professor, Department of Rheumatology, Leiden University Medical Centre.
| |
Collapse
|
39
|
van Tiel J, Kotek G, Reijman M, Bos PK, Bron EE, Klein S, Nasserinejad K, van Osch GJVM, Verhaar JAN, Krestin GP, Weinans H, Oei EHG. Is T1ρ Mapping an Alternative to Delayed Gadolinium-enhanced MR Imaging of Cartilage in the Assessment of Sulphated Glycosaminoglycan Content in Human Osteoarthritic Knees? An in Vivo Validation Study. Radiology 2015; 279:523-31. [PMID: 26588020 DOI: 10.1148/radiol.2015150693] [Citation(s) in RCA: 57] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
PURPOSE To determine if T1ρ mapping can be used as an alternative to delayed gadolinium-enhanced magnetic resonance imaging of cartilage (dGEMRIC) in the quantification of cartilage biochemical composition in vivo in human knees with osteoarthritis. MATERIALS AND METHODS This study was approved by the institutional review board. Written informed consent was obtained from all participants. Twelve patients with knee osteoarthritis underwent dGEMRIC and T1ρ mapping at 3.0 T before undergoing total knee replacement. Outcomes of dGEMRIC and T1ρ mapping were calculated in six cartilage regions of interest. Femoral and tibial cartilages were harvested during total knee replacement. Cartilage sulphated glycosaminoglycan (sGAG) and collagen content were assessed with dimethylmethylene blue and hydroxyproline assays, respectively. A four-dimensional multivariate mixed-effects model was used to simultaneously assess the correlation between outcomes of dGEMRIC and T1ρ mapping and the sGAG and collagen content of the articular cartilage. RESULTS T1 relaxation times at dGEMRIC showed strong correlation with cartilage sGAG content (r = 0.73; 95% credibility interval [CI] = 0.60, 0.83) and weak correlation with cartilage collagen content (r = 0.40; 95% CI: 0.18, 0.58). T1ρ relaxation times did not correlate with cartilage sGAG content (r = 0.04; 95% CI: -0.21, 0.28) or collagen content (r = -0.05; 95% CI = -0.31, 0.20). CONCLUSION dGEMRIC can help accurately measure cartilage sGAG content in vivo in patients with knee osteoarthritis, whereas T1ρ mapping does not appear suitable for this purpose. Although the technique is not completely sGAG specific and requires a contrast agent, dGEMRIC is a validated and robust method for quantifying cartilage sGAG content in human osteoarthritis subjects in clinical research.
Collapse
Affiliation(s)
- Jasper van Tiel
- From the Departments of Radiology (J.v.T., G.K., E.E.B., S.K., G.P.K., E.H.G.O.), Orthopedic Surgery (J.v.T., M.R., P.K.B., G.J.V.M.v.O., J.A.N.V.), Medical Informatics (E.E.B., S.K.), Biostatistics (K.N.), and Otorhinolaryngology (G.J.V.M.v.O.), Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, the Netherlands; Department of Biomechanical Engineering, Delft University of Technology, Delft, the Netherlands (H.W.); and Department of Orthopedics and Rheumatology, University Medical Center Utrecht, Utrecht, the Netherlands (H.W.)
| | - Gyula Kotek
- From the Departments of Radiology (J.v.T., G.K., E.E.B., S.K., G.P.K., E.H.G.O.), Orthopedic Surgery (J.v.T., M.R., P.K.B., G.J.V.M.v.O., J.A.N.V.), Medical Informatics (E.E.B., S.K.), Biostatistics (K.N.), and Otorhinolaryngology (G.J.V.M.v.O.), Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, the Netherlands; Department of Biomechanical Engineering, Delft University of Technology, Delft, the Netherlands (H.W.); and Department of Orthopedics and Rheumatology, University Medical Center Utrecht, Utrecht, the Netherlands (H.W.)
| | - Max Reijman
- From the Departments of Radiology (J.v.T., G.K., E.E.B., S.K., G.P.K., E.H.G.O.), Orthopedic Surgery (J.v.T., M.R., P.K.B., G.J.V.M.v.O., J.A.N.V.), Medical Informatics (E.E.B., S.K.), Biostatistics (K.N.), and Otorhinolaryngology (G.J.V.M.v.O.), Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, the Netherlands; Department of Biomechanical Engineering, Delft University of Technology, Delft, the Netherlands (H.W.); and Department of Orthopedics and Rheumatology, University Medical Center Utrecht, Utrecht, the Netherlands (H.W.)
| | - Pieter K Bos
- From the Departments of Radiology (J.v.T., G.K., E.E.B., S.K., G.P.K., E.H.G.O.), Orthopedic Surgery (J.v.T., M.R., P.K.B., G.J.V.M.v.O., J.A.N.V.), Medical Informatics (E.E.B., S.K.), Biostatistics (K.N.), and Otorhinolaryngology (G.J.V.M.v.O.), Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, the Netherlands; Department of Biomechanical Engineering, Delft University of Technology, Delft, the Netherlands (H.W.); and Department of Orthopedics and Rheumatology, University Medical Center Utrecht, Utrecht, the Netherlands (H.W.)
| | - Esther E Bron
- From the Departments of Radiology (J.v.T., G.K., E.E.B., S.K., G.P.K., E.H.G.O.), Orthopedic Surgery (J.v.T., M.R., P.K.B., G.J.V.M.v.O., J.A.N.V.), Medical Informatics (E.E.B., S.K.), Biostatistics (K.N.), and Otorhinolaryngology (G.J.V.M.v.O.), Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, the Netherlands; Department of Biomechanical Engineering, Delft University of Technology, Delft, the Netherlands (H.W.); and Department of Orthopedics and Rheumatology, University Medical Center Utrecht, Utrecht, the Netherlands (H.W.)
| | - Stefan Klein
- From the Departments of Radiology (J.v.T., G.K., E.E.B., S.K., G.P.K., E.H.G.O.), Orthopedic Surgery (J.v.T., M.R., P.K.B., G.J.V.M.v.O., J.A.N.V.), Medical Informatics (E.E.B., S.K.), Biostatistics (K.N.), and Otorhinolaryngology (G.J.V.M.v.O.), Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, the Netherlands; Department of Biomechanical Engineering, Delft University of Technology, Delft, the Netherlands (H.W.); and Department of Orthopedics and Rheumatology, University Medical Center Utrecht, Utrecht, the Netherlands (H.W.)
| | - Kazem Nasserinejad
- From the Departments of Radiology (J.v.T., G.K., E.E.B., S.K., G.P.K., E.H.G.O.), Orthopedic Surgery (J.v.T., M.R., P.K.B., G.J.V.M.v.O., J.A.N.V.), Medical Informatics (E.E.B., S.K.), Biostatistics (K.N.), and Otorhinolaryngology (G.J.V.M.v.O.), Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, the Netherlands; Department of Biomechanical Engineering, Delft University of Technology, Delft, the Netherlands (H.W.); and Department of Orthopedics and Rheumatology, University Medical Center Utrecht, Utrecht, the Netherlands (H.W.)
| | - Gerjo J V M van Osch
- From the Departments of Radiology (J.v.T., G.K., E.E.B., S.K., G.P.K., E.H.G.O.), Orthopedic Surgery (J.v.T., M.R., P.K.B., G.J.V.M.v.O., J.A.N.V.), Medical Informatics (E.E.B., S.K.), Biostatistics (K.N.), and Otorhinolaryngology (G.J.V.M.v.O.), Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, the Netherlands; Department of Biomechanical Engineering, Delft University of Technology, Delft, the Netherlands (H.W.); and Department of Orthopedics and Rheumatology, University Medical Center Utrecht, Utrecht, the Netherlands (H.W.)
| | - Jan A N Verhaar
- From the Departments of Radiology (J.v.T., G.K., E.E.B., S.K., G.P.K., E.H.G.O.), Orthopedic Surgery (J.v.T., M.R., P.K.B., G.J.V.M.v.O., J.A.N.V.), Medical Informatics (E.E.B., S.K.), Biostatistics (K.N.), and Otorhinolaryngology (G.J.V.M.v.O.), Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, the Netherlands; Department of Biomechanical Engineering, Delft University of Technology, Delft, the Netherlands (H.W.); and Department of Orthopedics and Rheumatology, University Medical Center Utrecht, Utrecht, the Netherlands (H.W.)
| | - Gabriel P Krestin
- From the Departments of Radiology (J.v.T., G.K., E.E.B., S.K., G.P.K., E.H.G.O.), Orthopedic Surgery (J.v.T., M.R., P.K.B., G.J.V.M.v.O., J.A.N.V.), Medical Informatics (E.E.B., S.K.), Biostatistics (K.N.), and Otorhinolaryngology (G.J.V.M.v.O.), Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, the Netherlands; Department of Biomechanical Engineering, Delft University of Technology, Delft, the Netherlands (H.W.); and Department of Orthopedics and Rheumatology, University Medical Center Utrecht, Utrecht, the Netherlands (H.W.)
| | - Harrie Weinans
- From the Departments of Radiology (J.v.T., G.K., E.E.B., S.K., G.P.K., E.H.G.O.), Orthopedic Surgery (J.v.T., M.R., P.K.B., G.J.V.M.v.O., J.A.N.V.), Medical Informatics (E.E.B., S.K.), Biostatistics (K.N.), and Otorhinolaryngology (G.J.V.M.v.O.), Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, the Netherlands; Department of Biomechanical Engineering, Delft University of Technology, Delft, the Netherlands (H.W.); and Department of Orthopedics and Rheumatology, University Medical Center Utrecht, Utrecht, the Netherlands (H.W.)
| | - Edwin H G Oei
- From the Departments of Radiology (J.v.T., G.K., E.E.B., S.K., G.P.K., E.H.G.O.), Orthopedic Surgery (J.v.T., M.R., P.K.B., G.J.V.M.v.O., J.A.N.V.), Medical Informatics (E.E.B., S.K.), Biostatistics (K.N.), and Otorhinolaryngology (G.J.V.M.v.O.), Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, the Netherlands; Department of Biomechanical Engineering, Delft University of Technology, Delft, the Netherlands (H.W.); and Department of Orthopedics and Rheumatology, University Medical Center Utrecht, Utrecht, the Netherlands (H.W.)
| |
Collapse
|
40
|
Liu W, Burdick JA, van Osch GJVM. Regulation Policy on Tissue Engineering and Regenerative Medicine in Asian-Pacific Region. Tissue Eng Part A 2015; 21:2779-80. [PMID: 26486210 DOI: 10.1089/ten.tea.2015.0466] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Wei Liu
- 1 Department of Plastic Surgery, Shanghai Tissue Engineering Key Laboratory, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai, P.R. China
| | - Jason A Burdick
- 2 Department of Bioengineering, University of Pennsylvania , Philadelphia, Pennsylvania
| | - Gerjo J V M van Osch
- 3 Departments of Orthopaedics and Otorhinolaryngology, Erasmus MC University Medical Center , Rotterdam, The Netherlands
| |
Collapse
|
41
|
Bomer N, den Hollander W, Ramos YFM, Bos SD, van der Breggen R, Lakenberg N, Pepers BA, van Eeden AE, Darvishan A, Tobi EW, Duijnisveld BJ, van den Akker EB, Heijmans BT, van Roon-Mom WMC, Verbeek FJ, van Osch GJVM, Nelissen RGHH, Slagboom PE, Meulenbelt I. Underlying molecular mechanisms of DIO2 susceptibility in symptomatic osteoarthritis. Ann Rheum Dis 2015; 74:1571-9. [PMID: 24695009 PMCID: PMC4516000 DOI: 10.1136/annrheumdis-2013-204739] [Citation(s) in RCA: 64] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2013] [Revised: 03/14/2014] [Accepted: 03/15/2014] [Indexed: 11/30/2022]
Abstract
OBJECTIVES To investigate how the genetic susceptibility gene DIO2 confers risk to osteoarthritis (OA) onset in humans and to explore whether counteracting the deleterious effect could contribute to novel therapeutic approaches. METHODS Epigenetically regulated expression of DIO2 was explored by assessing methylation of positional CpG-dinucleotides and the respective DIO2 expression in OA-affected and macroscopically preserved articular cartilage from end-stage OA patients. In a human in vitro chondrogenesis model, we measured the effects when thyroid signalling during culturing was either enhanced (excess T3 or lentiviral induced DIO2 overexpression) or decreased (iopanoic acid). RESULTS OA-related changes in methylation at a specific CpG dinucleotide upstream of DIO2 caused significant upregulation of its expression (β=4.96; p=0.0016). This effect was enhanced and appeared driven specifically by DIO2 rs225014 risk allele carriers (β=5.58, p=0.0006). During in vitro chondrogenesis, DIO2 overexpression resulted in a significant reduced capacity of chondrocytes to deposit extracellular matrix (ECM) components, concurrent with significant induction of ECM degrading enzymes (ADAMTS5, MMP13) and markers of mineralisation (ALPL, COL1A1). Given their concurrent and significant upregulation of expression, this process is likely mediated via HIF-2α/RUNX2 signalling. In contrast, we showed that inhibiting deiodinases during in vitro chondrogenesis contributed to prolonged cartilage homeostasis as reflected by significant increased deposition of ECM components and attenuated upregulation of matrix degrading enzymes. CONCLUSIONS Our findings show how genetic variation at DIO2 could confer risk to OA and raised the possibility that counteracting thyroid signalling may be a novel therapeutic approach.
Collapse
Affiliation(s)
- Nils Bomer
- Department of Molecular Epidemiology, LUMC, Leiden, The Netherlands
- IDEAL, The Netherlands
| | | | | | - Steffan D Bos
- Department of Molecular Epidemiology, LUMC, Leiden, The Netherlands
- Genomics Initiative, sponsored by the NCHA, Leiden, The Netherlands
| | | | - Nico Lakenberg
- Department of Molecular Epidemiology, LUMC, Leiden, The Netherlands
| | - Barry A Pepers
- Department of Human Genetics, LUMC, Leiden, The Netherlands
| | | | - Arash Darvishan
- Department of Imaging & BioInformatics, LIACS, Leiden, The Netherlands
| | - Elmar W Tobi
- Department of Molecular Epidemiology, LUMC, Leiden, The Netherlands
- IDEAL, The Netherlands
| | | | - Erik B van den Akker
- Department of Molecular Epidemiology, LUMC, Leiden, The Netherlands
- The Delft Bioinformatics Lab, Delft University of Technology, Delft, The Netherlands
| | - Bastiaan T Heijmans
- Department of Molecular Epidemiology, LUMC, Leiden, The Netherlands
- Genomics Initiative, sponsored by the NCHA, Leiden, The Netherlands
| | | | - Fons J Verbeek
- Department of Imaging & BioInformatics, LIACS, Leiden, The Netherlands
| | - Gerjo J V M van Osch
- Department of Orthopaedics, Erasmus MC, Rotterdam, The Netherlands
- Deptartment of Otorhinolaryngology, Erasmus MC, Rotterdam, The Netherlands
| | | | - P Eline Slagboom
- Department of Molecular Epidemiology, LUMC, Leiden, The Netherlands
- IDEAL, The Netherlands
- Genomics Initiative, sponsored by the NCHA, Leiden, The Netherlands
| | - Ingrid Meulenbelt
- Department of Molecular Epidemiology, LUMC, Leiden, The Netherlands
- Genomics Initiative, sponsored by the NCHA, Leiden, The Netherlands
| |
Collapse
|
42
|
Nimeskern L, Pleumeekers MM, Pawson DJ, Koevoet WLM, Lehtoviita I, Soyka MB, Röösli C, Holzmann D, van Osch GJVM, Müller R, Stok KS. Mechanical and biochemical mapping of human auricular cartilage for reliable assessment of tissue-engineered constructs. J Biomech 2015; 48:1721-9. [PMID: 26065333 DOI: 10.1016/j.jbiomech.2015.05.019] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2015] [Revised: 05/07/2015] [Accepted: 05/14/2015] [Indexed: 11/28/2022]
Abstract
It is key for successful auricular (AUR) cartilage tissue-engineering (TE) to ensure that the engineered cartilage mimics the mechanics of the native tissue. This study provides a spatial map of the mechanical and biochemical properties of human auricular cartilage, thus establishing a benchmark for the evaluation of functional competency in AUR cartilage TE. Stress-relaxation indentation (instantaneous modulus, Ein; maximum stress, σmax; equilibrium modulus, Eeq; relaxation half-life time, t1/2; thickness, h) and biochemical parameters (content of DNA; sulfated-glycosaminoglycan, sGAG; hydroxyproline, HYP; elastin, ELN) of fresh human AUR cartilage were evaluated. Samples were categorized into age groups and according to their harvesting region in the human auricle (for AUR cartilage only). AUR cartilage displayed significantly lower Ein, σmax, Eeq, sGAG content; and significantly higher t1/2, and DNA content than NAS cartilage. Large amounts of ELN were measured in AUR cartilage (>15% ELN content per sample wet mass). No effect of gender was observed for either auricular or nasoseptal samples. For auricular samples, significant differences between age groups for h, sGAG and HYP, and significant regional variations for Ein, σmax, Eeq, t1/2, h, DNA and sGAG were measured. However, only low correlations between mechanical and biochemical parameters were seen (R<0.44). In conclusion, this study established the first comprehensive mechanical and biochemical map of human auricular cartilage. Regional variations in mechanical and biochemical properties were demonstrated in the auricle. This finding highlights the importance of focusing future research on efforts to produce cartilage grafts with spatially tunable mechanics.
Collapse
Affiliation(s)
- Luc Nimeskern
- Institute for Biomechanics, ETH Zürich, Zürich, Switzerland
| | - Mieke M Pleumeekers
- Department of Otorhinolaryngology, Head and Neck Surgery, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | | | - Wendy L M Koevoet
- Department of Otorhinolaryngology, Head and Neck Surgery, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | | | - Michael B Soyka
- Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Zürich, Zürich, Switzerland
| | - Christof Röösli
- Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Zürich, Zürich, Switzerland
| | - David Holzmann
- Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Zürich, Zürich, Switzerland
| | - Gerjo J V M van Osch
- Department of Otorhinolaryngology, Head and Neck Surgery, Erasmus MC, University Medical Center, Rotterdam, The Netherlands; Department of Orthopaedics, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | - Ralph Müller
- Institute for Biomechanics, ETH Zürich, Zürich, Switzerland
| | - Kathryn S Stok
- Institute for Biomechanics, ETH Zürich, Zürich, Switzerland.
| |
Collapse
|
43
|
Narcisi R, Cleary MA, Brama PAJ, Hoogduijn MJ, Tüysüz N, ten Berge D, van Osch GJVM. Long-term expansion, enhanced chondrogenic potential, and suppression of endochondral ossification of adult human MSCs via WNT signaling modulation. Stem Cell Reports 2015; 4:459-72. [PMID: 25733021 PMCID: PMC4375944 DOI: 10.1016/j.stemcr.2015.01.017] [Citation(s) in RCA: 85] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2014] [Revised: 01/21/2015] [Accepted: 01/22/2015] [Indexed: 02/07/2023] Open
Abstract
Mesenchymal stem cells (MSCs) are a potential source of chondrogenic cells for the treatment of cartilage disorders, but loss of chondrogenic potential during in vitro expansion and the propensity of cartilage to undergo hypertrophic maturation impede their therapeutic application. Here we report that the signaling protein WNT3A, in combination with FGF2, supports long-term expansion of human bone marrow-derived MSCs. The cells retained their chondrogenic potential and other phenotypic and functional properties of multipotent MSCs, which were gradually lost in the absence of WNT3A. Moreover, we discovered that endogenous WNT signals are the main drivers of the hypertrophic maturation that follows chondrogenic differentiation. Inhibition of WNT signals during differentiation prevented calcification and maintained cartilage properties following implantation in a mouse model. By maintaining potency during expansion and preventing hypertrophic maturation following differentiation, the modulation of WNT signaling removes two major obstacles that impede the clinical application of MSCs in cartilage repair. WNT3A and FGF2 synergistically promote MSC proliferation WNT3A and FGF2 synergistically enhance MSC chondrogenic potential during expansion WNT3A and FGF2 maintain MSC characteristics over multiple passages In vitro WNT signaling modulation leads to stable cartilage formation in vivo
Collapse
Affiliation(s)
- Roberto Narcisi
- Department of Orthopaedics, Erasmus MC, University Medical Center, 3015 CN Rotterdam, the Netherlands
| | - Mairéad A Cleary
- Department of Orthopaedics, Erasmus MC, University Medical Center, 3015 CN Rotterdam, the Netherlands; Section of Veterinary Clinical Sciences, School of Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland
| | - Pieter A J Brama
- Section of Veterinary Clinical Sciences, School of Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland
| | - Martin J Hoogduijn
- Department of Internal Medicine, Erasmus MC, University Medical Center, 3015 CN Rotterdam, the Netherlands
| | - Nesrin Tüysüz
- Erasmus MC Stem Cell Institute, Department of Cell Biology, Erasmus MC, University Medical Center, 3015 CN Rotterdam, the Netherlands
| | - Derk ten Berge
- Erasmus MC Stem Cell Institute, Department of Cell Biology, Erasmus MC, University Medical Center, 3015 CN Rotterdam, the Netherlands.
| | - Gerjo J V M van Osch
- Department of Orthopaedics, Erasmus MC, University Medical Center, 3015 CN Rotterdam, the Netherlands; Department of Otorhinolaryngology, Erasmus MC, University Medical Center, 3015 CN Rotterdam, the Netherlands.
| |
Collapse
|
44
|
Muhonen V, Narcisi R, Nystedt J, Korhonen M, van Osch GJVM, Kiviranta I. Recombinant human type II collagen hydrogel provides a xeno-free 3D micro-environment for chondrogenesis of human bone marrow-derived mesenchymal stromal cells. J Tissue Eng Regen Med 2015; 11:843-854. [PMID: 25643647 DOI: 10.1002/term.1983] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2014] [Revised: 10/02/2014] [Accepted: 12/09/2014] [Indexed: 12/12/2022]
Abstract
Recombinant human type II collagen (rhCII) hydrogel was tested as a xeno-free micro-environment for the chondrogenesis of human bone marrow-derived mesenchymal stromal cells (BM-MSCs). The rhCII hydrogels were seeded with BM-MSCs and cultured in a xeno-free chondro-inductive medium for 14, 28 and 84 days. High-density pellet cultures served as controls. The samples were subjected to biochemical, histological and gene expression analyses. Although the cells deposited glycosaminoglycans into the extracellular space significantly more slowly in the rhCII hydrogels compared to the high-density pellets, a similar potential of matrix deposition was reached by the end of the 84-day culture. At day 28 of culture, the gene expression level for cartilage marker genes (i.e. genes encoding for Sox9 transcription factor, Collagen type II and Aggrecan) were considerably lower in the rhCII hydrogels than in the high-density pellets, but at the end of the 84-day culture period, all the cartilage marker genes analysed were expressed at a similar level. Interestingly, the expression of the matrix metallopeptidases (MMP)-13, MMP-14 and MMP-8, i.e. extracellular collagen network-degrading enzymes, were transiently upregulated in the rhCII hydrogel, indicating active matrix reorganization. This study demonstrated that the rhCII hydrogel functions as a xeno-free platform for BM-MSC chondrogenesis, although the process is delayed. The reversible catabolic reaction evoked by the rhCII hydrogel might be beneficial in graft integration in vivo and pinpoints the need to further explore the use of hydrogels containing recombinant extracellular matrix (ECM) proteins to induce the chondrogenesis of MSCs. Copyright © 2015 John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Virpi Muhonen
- Department of Surgery, Institute of Clinical Medicine, University of Helsinki, Finland.,Department of Orthopaedics and Traumatology, Hospital District of Helsinki and Uusimaa, Helsinki, Finland
| | - Roberto Narcisi
- Department of Orthopaedics, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
| | - Johanna Nystedt
- Finnish Red Cross Blood Service, Research and Cell Therapy Services, Helsinki, Finland
| | - Matti Korhonen
- Finnish Red Cross Blood Service, Research and Cell Therapy Services, Helsinki, Finland
| | - Gerjo J V M van Osch
- Department of Orthopaedics, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands.,Department of Otorhinolaryngology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
| | - Ilkka Kiviranta
- Department of Surgery, Institute of Clinical Medicine, University of Helsinki, Finland.,Department of Orthopaedics and Traumatology, Hospital District of Helsinki and Uusimaa, Helsinki, Finland
| |
Collapse
|
45
|
Utomo L, Pleumeekers MM, Nimeskern L, Nürnberger S, Stok KS, Hildner F, van Osch GJVM. Preparation and characterization of a decellularized cartilage scaffold for ear cartilage reconstruction. ACTA ACUST UNITED AC 2015; 10:015010. [PMID: 25586138 DOI: 10.1088/1748-6041/10/1/015010] [Citation(s) in RCA: 65] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Scaffolds are widely used to reconstruct cartilage. Yet, the fabrication of a scaffold with a highly organized microenvironment that closely resembles native cartilage remains a major challenge. Scaffolds derived from acellular extracellular matrices are able to provide such a microenvironment. Currently, no report specifically on decellularization of full thickness ear cartilage has been published. In this study, decellularized ear cartilage scaffolds were prepared and extensively characterized. Cartilage decellularization was optimized to remove cells and cell remnants from elastic cartilage. Following removal of nuclear material, the obtained scaffolds retained their native collagen and elastin contents as well as their architecture and shape. High magnification scanning electron microscopy showed no obvious difference in matrix density after decellularization. However, glycosaminoglycan content was significantly reduced, resulting in a loss of viscoelastic properties. Additionally, in contact with the scaffolds, human bone-marrow-derived mesenchymal stem cells remained viable and are able to differentiate toward the chondrogenic lineage when cultured in vitro. These results, including the ability to decellularize whole human ears, highlight the clinical potential of decellularization as an improved cartilage reconstruction strategy.
Collapse
Affiliation(s)
- Lizette Utomo
- Department of Otorhinolaryngology, Erasmus MC, University Medical Center Rotterdam, Wytemaweg 80, 3015 CN, Rotterdam, The Netherlands. Department of Orthopaedics, Erasmus MC, University Medical Center Rotterdam, Wytemaweg 80, 3015 CN, Rotterdam, The Netherlands. Faculty of Science and Technology, University of Twente, PO Box 217, 7500 AE Enschede, The Netherlands
| | | | | | | | | | | | | |
Collapse
|
46
|
Zwolanek D, Flicker M, Kirstätter E, Zaucke F, van Osch GJVM, Erben RG. β1 Integrins Mediate Attachment of Mesenchymal Stem Cells to Cartilage Lesions. Biores Open Access 2015; 4:39-53. [PMID: 26309781 PMCID: PMC4497673 DOI: 10.1089/biores.2014.0055] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Mesenchymal stem cells (MSC) may have great potential for cell-based therapies of osteoarthritis. However, after injection in the joint, only few cells adhere to defective articular cartilage and contribute to cartilage regeneration. Little is known about the molecular mechanisms of MSC attachment to defective articular cartilage. Here, we developed an ex vivo attachment system, using rat osteochondral explants with artificially created full-thickness cartilage defects in combination with genetically labeled MSC isolated from bone marrow of human placental alkaline phosphatase transgenic rats. Binding of MSC to full-thickness cartilage lesions was improved by serum, but not hyaluronic acid, and was dependent on the presence of divalent cations. Additional in vitro tests showed that rat MSC attach, in a divalent cation-dependent manner, to collagen I, collagen II, and fibronectin, but not to collagen XXII or cartilage oligomeric matrix protein (COMP). RGD peptides partially blocked the adhesion of MSC to fibronectin in vitro and to cartilage lesions ex vivo. Furthermore, the attachment of MSC to collagen I and II in vitro and to cartilage lesions ex vivo was almost completely abolished in the presence of a β1 integrin blocking antibody. In conclusion, our data suggest that attachment of MSC to ex vivo full-thickness cartilage lesions is almost entirely β1 integrin-mediated, whereby both RGD- and collagen-binding integrins are involved. These findings suggest a key role of integrins during MSC attachment to defective cartilage and may pave the way for improved MSC-based therapies in the future.
Collapse
Affiliation(s)
- Daniela Zwolanek
- Department of Biomedical Sciences, University of Veterinary Medicine , Vienna, Austria
| | - Magdalena Flicker
- Department of Biomedical Sciences, University of Veterinary Medicine , Vienna, Austria
| | - Elisabeth Kirstätter
- Department of Biomedical Sciences, University of Veterinary Medicine , Vienna, Austria
| | - Frank Zaucke
- Center for Biochemistry and Cologne Center for Musculoskeletal Biomechanics, Medical Faculty, University of Cologne , Cologne, Germany
| | - Gerjo J V M van Osch
- Department of Orthopaedics and Otorhinolaryngology, Erasmus MC, University Medical Center Rotterdam , Rotterdam, The Netherlands
| | - Reinhold G Erben
- Department of Biomedical Sciences, University of Veterinary Medicine , Vienna, Austria
| |
Collapse
|
47
|
Tsuchida AI, Beekhuizen M, 't Hart MC, Radstake TRDJ, Dhert WJA, Saris DBF, van Osch GJVM, Creemers LB. Cytokine profiles in the joint depend on pathology, but are different between synovial fluid, cartilage tissue and cultured chondrocytes. Arthritis Res Ther 2014; 16:441. [PMID: 25256035 PMCID: PMC4201683 DOI: 10.1186/s13075-014-0441-0] [Citation(s) in RCA: 115] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2014] [Accepted: 08/28/2014] [Indexed: 12/20/2022] Open
Abstract
Introduction This study aimed to evaluate whether profiles of several soluble mediators in synovial fluid and cartilage tissue are pathology-dependent and how their production is related to in vitro tissue formation by chondrocytes from diseased and healthy tissue. Methods Samples were obtained from donors without joint pathology (n = 39), with focal defects (n = 65) and osteoarthritis (n = 61). A multiplex bead assay (Luminex) was performed measuring up to 21 cytokines: Interleukin (IL)-1α, IL-1β, IL-1RA, IL-4, IL-6, IL-6Rα, IL-7, IL-8, IL-10, IL-13, tumor necrosis factor (TNF)α, Interferon (IFN)γ, oncostatin M (OSM), leukemia inhibitory factor (LIF), adiponectin, leptin, monocyte chemotactic factor (MCP)1, RANTES, basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), vascular growth factor (VEGF). Results In synovial fluid of patients with cartilage pathology, IL-6, IL-13, IFNγ and OSM levels were higher than in donors without joint pathology (P ≤0.001). IL-13, IFNγ and OSM were also different between donors with cartilage defects and OA (P <0.05). In cartilage tissue from debrided defects, VEGF was higher than in non-pathological or osteoarthritic joints (P ≤0.001). IL-1α, IL-6, TNFα and OSM concentrations (in ng/ml) were markedly higher in cartilage tissue than in synovial fluid (P <0.01). Culture of chondrocytes generally led to a massive induction of most cytokines (P <0.001). Although the release of inflammatory cytokines was also here dependent on the pathological condition (P <0.001) the actual profiles were different from tissue or synovial fluid and between non-expanded and expanded chondrocytes. Cartilage formation was lower by healthy unexpanded chondrocytes than by osteoarthritic or defect chondrocytes. Conclusions Several pro-inflammatory, pro-angiogenic and pro-repair cytokines were elevated in joints with symptomatic cartilage defects and/or osteoarthritis, although different cytokines were elevated in synovial fluid compared to tissue or cells. Hence a clear molecular profile was evident dependent on disease status of the joint, which however changed in composition depending on the biological sample analysed. These alterations did not affect in vitro tissue formation with these chondrocytes, as this was at least as effective or even better compared to healthy chondrocytes.
Collapse
|
48
|
van Buul GM, Siebelt M, Leijs MJC, Bos PK, Waarsing JH, Kops N, Weinans H, Verhaar JAN, Bernsen MR, van Osch GJVM. Mesenchymal stem cells reduce pain but not degenerative changes in a mono-iodoacetate rat model of osteoarthritis. J Orthop Res 2014; 32:1167-74. [PMID: 24839120 DOI: 10.1002/jor.22650] [Citation(s) in RCA: 67] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/23/2014] [Accepted: 04/24/2014] [Indexed: 02/04/2023]
Abstract
We studied the effects of intra-articularly injected bone marrow derived mesenchymal stem cells (MSCs), as well as freshly isolated bone marrow mononuclear cells (BMMNCs), on pain, cartilage damage, bone changes and inflammation in an in-vivo rat osteoarthritis (OA) model. OA was induced unilaterally by injection of mono-iodoacetate (MIA) and allowed to develop for 3 weeks. Then, animals were treated by intra-articular injection with MSCs, BMMNCs, or saline as a control. Four weeks later, pain was assessed with an incapitance tester, subchondral bone alterations were measured with µCT and cartilage quality and joint inflammation were assessed by histological analysis. Animals treated with MSCs distributed significantly more weight to the affected limb after treatment, which was not observed in the other groups. No statistically significant differences between treatment groups regarding cartilage damage, subchondral bone alterations and synovial inflammation were observed. Additional cell tracking experiments indicated adequate intra-articular cell injection and cell survival up to 2 weeks. In our OA model, injected MSCs were able to reduce MIA induced pain, as measured by an increased weight distribution to the affected limb. No statistically significant effects of the cellular therapies on structural damage and synovial inflammation were found.
Collapse
Affiliation(s)
- Gerben M van Buul
- Department of Orthopaedics, Erasmus MC, Wytemaweg 80, Rotterdam, The Netherlands; Department of Radiology, Erasmus MC, Rotterdam, The Netherlands
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Affiliation(s)
- Gerjo J V M van Osch
- 1 Department of Orthopaedics, Erasmus MC, University Medical Center Rotterdam , Rotterdam, the Netherlands
| | | | | |
Collapse
|
50
|
Jenner F, IJpma A, Cleary M, Heijsman D, Narcisi R, van der Spek PJ, Kremer A, van Weeren R, Brama P, van Osch GJVM. Differential gene expression of the intermediate and outer interzone layers of developing articular cartilage in murine embryos. Stem Cells Dev 2014; 23:1883-98. [PMID: 24738827 DOI: 10.1089/scd.2013.0235] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Nascent embryonic joints, interzones, contain a distinct cohort of progenitor cells responsible for the formation of the majority of articular tissues. However, to date the interzone has largely been studied using in situ analysis for candidate genes in the context of the embryo rather than using an unbiased genome-wide expression analysis on isolated interzone cells, leaving significant controversy regarding the exact role of the intermediate and outer interzone layers in joint formation. Therefore, in this study, using laser capture microdissection (three biological replicates), we selectively harvested the intermediate and outer interzones of mouse embryos at gestational age 15.5 days, just prior to cavitation, when the differences between the layers should be most profound. Microarray analysis (Agilent Whole Mouse Genome Oligo Microarrays) was performed and the differential gene expression between the intermediate interzone cells and outer interzone cells was examined by performing a two-sided paired Student's t-test and pathway analysis. One hundred ninety-seven genes were differentially expressed (≥ 2-fold) between the intermediate interzone and the outer interzone with a P-value ≤ 0.01. Of these, 91 genes showed higher expression levels in the intermediate interzone and 106 were expressed higher in the outer interzone. Pathway analysis of differentially expressed genes suggests an important role for inflammatory processes in the interzone layers, especially in the intermediate interzone, and hence in joint and articular cartilage development. The high representation of genes relevant to chondrocyte hypertrophy and endochondral ossification in the outer interzone suggests that it undergoes endochondral ossification.
Collapse
Affiliation(s)
- Florien Jenner
- 1 Equine University Hospital, Department of Companion Animals and Horses, University of Veterinary Medicine Vienna , Vienna, Austria
| | | | | | | | | | | | | | | | | | | |
Collapse
|